中药配伍优化干预动脉粥样硬化易损斑块作用的研究
|
摘要
目前,动脉粥样硬化易损斑块作导致急性心血管事件方面的重要性已受到广泛重视。改善易损斑块内部成分,使其趋于稳定,成为防治急性心血管事件的重要内容。本研究在得出与急性心血管事件有关的中医证候要素的基础上,选取相应中药。采用均匀设计法探索了稳定斑块最佳中药组分配伍组合,这对于动脉粥样硬化和冠心病的防治无疑具有重要意义。
1临床研究：冠心病住院患者中医证候分布规律的多中心研究
1.1目的
通过对1005例冠心病住院患者进行横断面调查,观察冠心病住院患者医证候要素分布的特点；探索中医证候要素与急性心血管事件发生的关系,从而为冠心病中医临床辨治及药物研发提供依据。
1.2方法
收集9家医院1005例冠心病住院患者,观察冠心病住院患者的中医证候要素分布的特点。并通过前瞻性调查研究方法,随访1年,观察上述患者心血管事件发生情况,通过主成分Logistic回归分析发生心血管事件患者的中医证候要素分布特点。
1.3结果
冠心病住院患者最常见证候要素由高到低分别为血瘀(81.4%),气虚(56.8%)、痰浊(48.5%)、阴虚(25.1%)。随访1年,其中发生急性心血管事件的患者有66例,未发生急性心血管事件的患者有939例。经主成分Logistic回归方法分析,结果显示主要由气虚、阴虚组成的主成分2在Logistic回归中有统计学差异(P=0.036)。
1.4结论
血瘀、气虚、痰浊、阴虚是冠心病住院患者的主要证候要素,体现出本虚标实的特点。气虚、阴虚可能是冠心病住院患者随访发生急性心血管事件相关的证侯要素,值得深入研究。
2基础研究：中药配伍优化干预ApoE基因缺陷小鼠动脉粥样硬化易损斑块作用的研究
2.1目的
在前期研究活血解毒中药具有较好的稳定易损斑块作用基础上,结合临床冠心病患者主要证候要素,基于均匀设计方法观察中药复方对ApoE基因缺陷小鼠主动脉粥样硬化易损斑块稳定性的作用,探索最佳组方和配比关系。
2.2方法
选取虎杖、三七、瓜蒌、何首鸟四种中药,采用均匀设计法“4因子8水平表”分组设计,将这四种药物的提取物分成8个给药组。100只ApoE-/-,小鼠经“西方膳食”饲料喂养13周后,将小鼠随机分为10组：8个药物组、阿托伐他汀组、模型组各10只。继续高脂喂养并给予相应药物治疗13周后,处死小鼠：首先取出主动脉,进行大体病理形态观察,并进行苏丹Ⅳ染色；然后取小鼠主动脉根部的3个横切面,分别行HE染色、Movat染色以及免疫组织化学染色法观察斑块内部成分；同时取血清。观察项目：(Ⅰ)大体主动脉：计算斑块／内膜面积的比值；(2)主动脉根部横切面：计算包括斑块面积,细胞外脂质(EL)、泡沫细胞(FC)、胶原成分(CA)以及平滑肌细胞(SMC)各自占斑块面积的百分比；(3)免疫组化染色观察主动脉根部AS斑块内PPAR-γ的表达,并计算阳性面积与斑块面积的比值；(4)测定血脂含量。最后采用易损指数(Ⅵ)综合评价药物对小鼠主动脉斑块稳定性的影响。公式为：易损指数(VI)=(EL+FC)/(CA+SMC)。以易损指数为筛选指标,经均匀设计回归分析获得“最佳组方及配比关系”。
2.3结果
2.3.1主动脉大体标本
各组小鼠动脉均可见红染的动脉粥样硬化斑块,明显的纤维斑块,散在分布。模型组主动脉管壁病变最为严重,粥样斑块和脂纹累积范围广泛,程度重。与模型组比较,药物组2、3、6、7、8及阿托伐他汀组小鼠主动脉斑块／内膜面积比值有明显下降,有显著差异(P<0.05)。
2.3.2主动脉根部横切面
各组小鼠主动脉根部横切片H-E染色和Movat五色套染法可看到明显的动脉粥样硬化斑块,内膜不对称增厚,被大量泡沫细胞覆盖的薄的纤维帽,细胞外基质中可见胆固醇结晶,以及富含脂质的坏死物质,显示出易损斑块特征。某些标本血管中层变薄,弹性纤维断裂,甚至消失。Movat染色下,胶原组织染成黄色。SMα-actin免疫组化染色下,阳性平滑肌即染成棕黄色。与模型组比较,各药物组小鼠主动脉横切面AS斑块面积无明显差异(P>0.05)。
2.3.3 AS斑块内部成分
EL含量比较,药物组5、7较模型组明显增加(P<0.05),其余各药物组及阿托伐他汀组与模型组无差异(P<0.05)。FC含量比较,与模型组相比较,各药物组及阿托伐他汀组均无显著性差异(P>0.05)。CA含量比较,与模型组比较,药物组3、4、6、7、8及阿托伐他汀组明显增加(P<0.05,P<0.01)。SMC含量比较,药物组1、2、3、4、8及阿托伐他汀组均明显增多(P<0.05,P<0.01)。
2.3.4AS斑块PPAR-γ含量
与模型组比较,药物组2、3、4、6、7、8及阿托伐他汀组小鼠斑块内PPAR-y蛋白阳性表达明显增加(P<0.05)。
2.3.5血脂
与模型组比较,各药物组血脂(包括TC、TG、HDL、LDL)均无明显差异(P>0.05)。
2.3.6评估斑块稳定性
与模型组相比,药物组1、3、4、6、7、8、阿托伐他汀组小鼠主动脉斑块易损指数均显著降低(P<0.05),其中以实验组8降低最为显著(P<0.01)。
2.3.7中药配伍优化结果
以易损指数为筛选指标,经均匀设计回归分析获得“最佳组方及配比关系”。配方1：虎杖0.3604克,瓜蒌0.3604克,何首乌0.1834克。配方2：虎杖0.3604克,何首乌0.1606克。
2.4结论
由虎杖、三七、瓜蒌、何首乌组成的中药复方,可不同程度地降低ApoE-/-小鼠主动脉粥样硬化斑块易损指数,具有一定稳定动脉粥样硬化斑块的作用。通过多元回归分析,具有最佳稳定斑块作用的中药组方及配比关系为：虎杖0.3604克,瓜蒌0.3604克,何首乌0.183克g,或虎杖0.3604克,何首乌0.1606克,为下一步验证奠定了基础。
Nowadays, vulnerable atherosclerotic plaque (VAP) has been highlighted for its role in leading to acute cardiovascular events. Thus, it is regarded as an important strategy to prevent the incidence of acute cardiovascular events by changing the composition of VAP to make it stable. Based on the result which TCM syndrome elements are relevant to acute cardiovascular events, we choose corresponding Chinese herbs. We further explored the optimized combination and proportion of herbal extractives in stabilizing VAP by uniform design, which is of great importance for developing effective Chinese medicine in preventing and treating AS and coronary heart disease.
1 Clinical research:Multi-central research of TCM syndrome elements of hospitalized patients with coronary heart disease
1.1 Objective
To study distribution of TCM syndrome elements in 1005 CHD patients in hospital; to explore the correlation of TCM syndrome elements and cardiovascular events, so as to provide the clinical evidence for CHD syndrome differentiation and treatment with TCM, as well as the development of new Chinese compound prescribtion.
1.2 Method
By cross-sectional research method, we analyzed the distribution of TCM syndrome elements in 1005 CHD patients from 9 hospitals; by prospective research method, we studied the distribution of TCM syndrome elements in CHD patients with cardiovascular events in 1 year and explored the correlation of TCM syndrome elements and cardiovascular events through the principal component analysis and logistic regression analysis method.
1.3 Result
The proportion of chief TCM syndrome elements in CHD patients in descending order are blood stasis (81.4%), qi deficiency (56.8% ), turbid phlegm (48.5% ), yin deficiency (25.1%). After 1 year follow-up, there are 66 CHD patients who happen to cardiovascular events, and the other 939 CHD patients who have no cardiovascular events. The analytic results of principal component analysis and logistic regression analysis method demonstrated that the second principal component had statistical significance in logistic regression (P=0.036), and the second principal component mainly consisted of qi deficiency and yin deficiency.
1.4 Conclusion
Blood stasis, qi deficiency, turbid phlegm, yin deficiency were main syndrome elements of CHD patients. And that result reflected the feature of deficiency in origin and excess in superficislity. Qi deficiency and yin definciency might be the relevant TCM syndrome elements to the CHD patients who happen to cardiovascular events in 1 year follow up.
2 Experimental research:Study the effect of Chinese herbs on atherosclerotic vulnerable plaque stability of ApoE gene-deficient (ApoE) mice and explor the optimized combination and proportion of chinese herbs
2.1 Objective
Based the results of previous study that the chinses herbs of activating blood circulation and detoxicationg could stabilize atherosclerotic plaque, we combined the main sysdrome elements of CHD patients in clinic. We would study the effect of Chinese herbs on the stability of atherosclerotic vulnerable plaque in the aortic roots of fat-fed ApoE-/- mice and explore the optimized combination and proportion of Chinese herbs by uniform design.
2.2 Method
We chose giant knotweed rhizome, panax pseudo-ginseng, snakegourd fruit, and polygonum multiflorum. A uniform design with 4-factor 8-level table was used in this study. According to the table, the four Chinese herb extractive (giant knotweed rhizome, panax pseudo-ginseng, snakegourd fruit, and polygonum multiflorum) were composed for 8 medication administration groups (No.1 group-No.8 group). One hundred ApoE mice were fed a high-fat diet for 13 weeks until the mature atherosclerotic plaques formed. Thereafter, they were randomized to ten groups (10 in each group) and fed a high-fat diet for subsequent 13 weeks:8 medication administration groups, atorvastatin group, and control group. Every group was medicated with respective drug in a clinically relevant dose for another 13 weeks. Then all the mice were sacrificed at the end of experiment. For each mouse, the aorta was dissected out and stained with SudanⅣfor subsequent assessment of atherosclerotic lesion area. Cross sections of aortic roots were prepared and stained with H-E, a modified Movat pentachrome stain, or immunohistochemistry stain respectively. The blood was collected for determination of blood lipids. The observe items included:(1) en face whole of aorta: the atherosclerotic plaques (red stained)/ aortic intimal surface area in each aorta. (2) histological cross sectional aortic sample: the area of atherosclerotic plaque, the percentage of extracelluar lipids (EL), foam cells (FC), collagen (CA) and smooth muscle cells (SMC) in plaque. (3) Immunohistochemical staining for the expression of PPAR-γ, positive staining areas were measured and expressed as a percentage of the whole plaque area. (4) Determination of serum lipid levels. The effect on plaque stability was evaluated by using the vulnerability index (Ⅵ). TheⅥwas expressed as the area ratio of foam cells and extracellular lipids to collagens and smooth muscle cells. Taking theⅥas the screen index, we explored the optimized combination and proportion of Chinese herbs by regression analysis of uniform design.
2.3 Result
2.3.1 En face whole aortic sample
In each group, the atherosclerotic plaques (red stained) were clearly observed and predominantly complex fibrous plaques, which were scattered in the entire aorta. Compared with control group, the No.2 group, No.3 group, No.6 group, No.7 group, No.8 group, and atorvastatin group was associated with a significant decrease in the plaque area (P<0.05).
2.3.2 Histological cross sectional aortic sample
HE staining and Movat's pentachrome staining within the aortic cross section revealed that the atherosclerotic plaques in ApoE-deficient mice were an asymmetrically thickened intima composed with a thin fibrous cap, usually buried with foam cells, and a lipid-rich necrotic core with cholesterol clefs within the extracellular matrix, that was typical morphologic features of vulnerable plaque. In some cases, the vascular media was thinned, and elastic fibers were broken, even disappeared. The collagen was yellow stained by Movat staining, and the positive of PPAR-γexpression was brown by immunohistochemical staining. As for the cross sectional area of atherosclerotic plaques within aorta, there was no significant difference among all drug treated group compared with control group (P>0.05).
2.3.3 Atherosclerotic plaque composition
As for extracellular lipids area, compared with control group, No.5 and No.7 group had a marked increase (P<0.05), the other groups and atrovastatin group had no significant difference. As for foam cell area, compared with control group, there was no significant difference among all groups (P>0.05). As for the collagen area, compared with control group, No.3 group, No.4 group, No.6 group, No.7 group, No.8 group, and atorvastatin goup was associated with a significant increase (P<0.05). As for the smooth muscle cell area, compared with control group, No.1 group, No.2 group, No.3 group, No.4 group, No.8 group, and atorvastatin group was associated with a significant increase (P>0.05).
2.3.4 Expression of PPAR-γin the aortic plaque
Compared with the control group, No.2 group, No.3 group, No.4 group, No.6 group, No.7 group, No.8 group, and atorvastatin group was associated with a a marked increase in expression of PPAR-y (P<0.05).
2.3.5 Plasma lipid levels
Compared with controls, there was no statistically difference among all drug treated group (P>0.05) in the level of TC, TG, LDL and HDL respectively.
2.3.6 Evaluation of plaque stability
Compared with the control group, No.1 group, No.3 group, No.4 group, No.6 group, No.7 group, No.8 group, and atorvastatin group was associated with a significant reduction in the vulnerability index (Ⅵ) (P<0.05). And the vulnerability index of No.8 group was minimal (P<0.01).
2.3.7 Optimized combination and proportion of Chinese herbs
Taking the vulnerability index as the screen index and multivariant regression analysis of uniform design, we got the optimized combination and proportion of Chinese herbs. The first optimized combination:giant knotweed rhizome 0.3604g, snakegourd fruit 0.3604g, polygonum multiflorum 0.1834g. The second optimized combination:giant knotweed rhizome 0.3604g, polygonum multiflorum 0.1606g.
2.4 Conclusion
The Chinese medicine compound prescription (giant knotweed rhizome, panax pseudo-ginseng, snakegourd fruit, and polygonum multiflorum) had a reduction in the vulnerability index (VI) in ApoE-/- mice which indicated the Chinese medicine compound prescription had potential effect on stabilizing atherosclerotic plaque. By the multivariant regression method, the optimized combination and proportion which could stabilize the atherosclerotic plaque were that the first optimized combination: giant knotweed rhizome 0.3604g, snakegourd fruit 0.3604g, polygonum multiflorum 0.1834g; the second optimized combination:giant knotweed rhizome 0.3604g, polygonum multiflorum 0.1606g, which laid a foundation of the optimized combination verificafion.
1临床研究：冠心病住院患者中医证候分布规律的多中心研究
1.1目的
通过对1005例冠心病住院患者进行横断面调查,观察冠心病住院患者医证候要素分布的特点；探索中医证候要素与急性心血管事件发生的关系,从而为冠心病中医临床辨治及药物研发提供依据。
1.2方法
收集9家医院1005例冠心病住院患者,观察冠心病住院患者的中医证候要素分布的特点。并通过前瞻性调查研究方法,随访1年,观察上述患者心血管事件发生情况,通过主成分Logistic回归分析发生心血管事件患者的中医证候要素分布特点。
1.3结果
冠心病住院患者最常见证候要素由高到低分别为血瘀(81.4%),气虚(56.8%)、痰浊(48.5%)、阴虚(25.1%)。随访1年,其中发生急性心血管事件的患者有66例,未发生急性心血管事件的患者有939例。经主成分Logistic回归方法分析,结果显示主要由气虚、阴虚组成的主成分2在Logistic回归中有统计学差异(P=0.036)。
1.4结论
血瘀、气虚、痰浊、阴虚是冠心病住院患者的主要证候要素,体现出本虚标实的特点。气虚、阴虚可能是冠心病住院患者随访发生急性心血管事件相关的证侯要素,值得深入研究。
2基础研究：中药配伍优化干预ApoE基因缺陷小鼠动脉粥样硬化易损斑块作用的研究
2.1目的
在前期研究活血解毒中药具有较好的稳定易损斑块作用基础上,结合临床冠心病患者主要证候要素,基于均匀设计方法观察中药复方对ApoE基因缺陷小鼠主动脉粥样硬化易损斑块稳定性的作用,探索最佳组方和配比关系。
2.2方法
选取虎杖、三七、瓜蒌、何首鸟四种中药,采用均匀设计法“4因子8水平表”分组设计,将这四种药物的提取物分成8个给药组。100只ApoE-/-,小鼠经“西方膳食”饲料喂养13周后,将小鼠随机分为10组：8个药物组、阿托伐他汀组、模型组各10只。继续高脂喂养并给予相应药物治疗13周后,处死小鼠：首先取出主动脉,进行大体病理形态观察,并进行苏丹Ⅳ染色；然后取小鼠主动脉根部的3个横切面,分别行HE染色、Movat染色以及免疫组织化学染色法观察斑块内部成分；同时取血清。观察项目：(Ⅰ)大体主动脉：计算斑块／内膜面积的比值；(2)主动脉根部横切面：计算包括斑块面积,细胞外脂质(EL)、泡沫细胞(FC)、胶原成分(CA)以及平滑肌细胞(SMC)各自占斑块面积的百分比；(3)免疫组化染色观察主动脉根部AS斑块内PPAR-γ的表达,并计算阳性面积与斑块面积的比值；(4)测定血脂含量。最后采用易损指数(Ⅵ)综合评价药物对小鼠主动脉斑块稳定性的影响。公式为：易损指数(VI)=(EL+FC)/(CA+SMC)。以易损指数为筛选指标,经均匀设计回归分析获得“最佳组方及配比关系”。
2.3结果
2.3.1主动脉大体标本
各组小鼠动脉均可见红染的动脉粥样硬化斑块,明显的纤维斑块,散在分布。模型组主动脉管壁病变最为严重,粥样斑块和脂纹累积范围广泛,程度重。与模型组比较,药物组2、3、6、7、8及阿托伐他汀组小鼠主动脉斑块／内膜面积比值有明显下降,有显著差异(P<0.05)。
2.3.2主动脉根部横切面
各组小鼠主动脉根部横切片H-E染色和Movat五色套染法可看到明显的动脉粥样硬化斑块,内膜不对称增厚,被大量泡沫细胞覆盖的薄的纤维帽,细胞外基质中可见胆固醇结晶,以及富含脂质的坏死物质,显示出易损斑块特征。某些标本血管中层变薄,弹性纤维断裂,甚至消失。Movat染色下,胶原组织染成黄色。SMα-actin免疫组化染色下,阳性平滑肌即染成棕黄色。与模型组比较,各药物组小鼠主动脉横切面AS斑块面积无明显差异(P>0.05)。
2.3.3 AS斑块内部成分
EL含量比较,药物组5、7较模型组明显增加(P<0.05),其余各药物组及阿托伐他汀组与模型组无差异(P<0.05)。FC含量比较,与模型组相比较,各药物组及阿托伐他汀组均无显著性差异(P>0.05)。CA含量比较,与模型组比较,药物组3、4、6、7、8及阿托伐他汀组明显增加(P<0.05,P<0.01)。SMC含量比较,药物组1、2、3、4、8及阿托伐他汀组均明显增多(P<0.05,P<0.01)。
2.3.4AS斑块PPAR-γ含量
与模型组比较,药物组2、3、4、6、7、8及阿托伐他汀组小鼠斑块内PPAR-y蛋白阳性表达明显增加(P<0.05)。
2.3.5血脂
与模型组比较,各药物组血脂(包括TC、TG、HDL、LDL)均无明显差异(P>0.05)。
2.3.6评估斑块稳定性
与模型组相比,药物组1、3、4、6、7、8、阿托伐他汀组小鼠主动脉斑块易损指数均显著降低(P<0.05),其中以实验组8降低最为显著(P<0.01)。
2.3.7中药配伍优化结果
以易损指数为筛选指标,经均匀设计回归分析获得“最佳组方及配比关系”。配方1：虎杖0.3604克,瓜蒌0.3604克,何首乌0.1834克。配方2：虎杖0.3604克,何首乌0.1606克。
2.4结论
由虎杖、三七、瓜蒌、何首乌组成的中药复方,可不同程度地降低ApoE-/-小鼠主动脉粥样硬化斑块易损指数,具有一定稳定动脉粥样硬化斑块的作用。通过多元回归分析,具有最佳稳定斑块作用的中药组方及配比关系为：虎杖0.3604克,瓜蒌0.3604克,何首乌0.183克g,或虎杖0.3604克,何首乌0.1606克,为下一步验证奠定了基础。
Nowadays, vulnerable atherosclerotic plaque (VAP) has been highlighted for its role in leading to acute cardiovascular events. Thus, it is regarded as an important strategy to prevent the incidence of acute cardiovascular events by changing the composition of VAP to make it stable. Based on the result which TCM syndrome elements are relevant to acute cardiovascular events, we choose corresponding Chinese herbs. We further explored the optimized combination and proportion of herbal extractives in stabilizing VAP by uniform design, which is of great importance for developing effective Chinese medicine in preventing and treating AS and coronary heart disease.
1 Clinical research:Multi-central research of TCM syndrome elements of hospitalized patients with coronary heart disease
1.1 Objective
To study distribution of TCM syndrome elements in 1005 CHD patients in hospital; to explore the correlation of TCM syndrome elements and cardiovascular events, so as to provide the clinical evidence for CHD syndrome differentiation and treatment with TCM, as well as the development of new Chinese compound prescribtion.
1.2 Method
By cross-sectional research method, we analyzed the distribution of TCM syndrome elements in 1005 CHD patients from 9 hospitals; by prospective research method, we studied the distribution of TCM syndrome elements in CHD patients with cardiovascular events in 1 year and explored the correlation of TCM syndrome elements and cardiovascular events through the principal component analysis and logistic regression analysis method.
1.3 Result
The proportion of chief TCM syndrome elements in CHD patients in descending order are blood stasis (81.4%), qi deficiency (56.8% ), turbid phlegm (48.5% ), yin deficiency (25.1%). After 1 year follow-up, there are 66 CHD patients who happen to cardiovascular events, and the other 939 CHD patients who have no cardiovascular events. The analytic results of principal component analysis and logistic regression analysis method demonstrated that the second principal component had statistical significance in logistic regression (P=0.036), and the second principal component mainly consisted of qi deficiency and yin deficiency.
1.4 Conclusion
Blood stasis, qi deficiency, turbid phlegm, yin deficiency were main syndrome elements of CHD patients. And that result reflected the feature of deficiency in origin and excess in superficislity. Qi deficiency and yin definciency might be the relevant TCM syndrome elements to the CHD patients who happen to cardiovascular events in 1 year follow up.
2 Experimental research:Study the effect of Chinese herbs on atherosclerotic vulnerable plaque stability of ApoE gene-deficient (ApoE) mice and explor the optimized combination and proportion of chinese herbs
2.1 Objective
Based the results of previous study that the chinses herbs of activating blood circulation and detoxicationg could stabilize atherosclerotic plaque, we combined the main sysdrome elements of CHD patients in clinic. We would study the effect of Chinese herbs on the stability of atherosclerotic vulnerable plaque in the aortic roots of fat-fed ApoE-/- mice and explore the optimized combination and proportion of Chinese herbs by uniform design.
2.2 Method
We chose giant knotweed rhizome, panax pseudo-ginseng, snakegourd fruit, and polygonum multiflorum. A uniform design with 4-factor 8-level table was used in this study. According to the table, the four Chinese herb extractive (giant knotweed rhizome, panax pseudo-ginseng, snakegourd fruit, and polygonum multiflorum) were composed for 8 medication administration groups (No.1 group-No.8 group). One hundred ApoE mice were fed a high-fat diet for 13 weeks until the mature atherosclerotic plaques formed. Thereafter, they were randomized to ten groups (10 in each group) and fed a high-fat diet for subsequent 13 weeks:8 medication administration groups, atorvastatin group, and control group. Every group was medicated with respective drug in a clinically relevant dose for another 13 weeks. Then all the mice were sacrificed at the end of experiment. For each mouse, the aorta was dissected out and stained with SudanⅣfor subsequent assessment of atherosclerotic lesion area. Cross sections of aortic roots were prepared and stained with H-E, a modified Movat pentachrome stain, or immunohistochemistry stain respectively. The blood was collected for determination of blood lipids. The observe items included:(1) en face whole of aorta: the atherosclerotic plaques (red stained)/ aortic intimal surface area in each aorta. (2) histological cross sectional aortic sample: the area of atherosclerotic plaque, the percentage of extracelluar lipids (EL), foam cells (FC), collagen (CA) and smooth muscle cells (SMC) in plaque. (3) Immunohistochemical staining for the expression of PPAR-γ, positive staining areas were measured and expressed as a percentage of the whole plaque area. (4) Determination of serum lipid levels. The effect on plaque stability was evaluated by using the vulnerability index (Ⅵ). TheⅥwas expressed as the area ratio of foam cells and extracellular lipids to collagens and smooth muscle cells. Taking theⅥas the screen index, we explored the optimized combination and proportion of Chinese herbs by regression analysis of uniform design.
2.3 Result
2.3.1 En face whole aortic sample
In each group, the atherosclerotic plaques (red stained) were clearly observed and predominantly complex fibrous plaques, which were scattered in the entire aorta. Compared with control group, the No.2 group, No.3 group, No.6 group, No.7 group, No.8 group, and atorvastatin group was associated with a significant decrease in the plaque area (P<0.05).
2.3.2 Histological cross sectional aortic sample
HE staining and Movat's pentachrome staining within the aortic cross section revealed that the atherosclerotic plaques in ApoE-deficient mice were an asymmetrically thickened intima composed with a thin fibrous cap, usually buried with foam cells, and a lipid-rich necrotic core with cholesterol clefs within the extracellular matrix, that was typical morphologic features of vulnerable plaque. In some cases, the vascular media was thinned, and elastic fibers were broken, even disappeared. The collagen was yellow stained by Movat staining, and the positive of PPAR-γexpression was brown by immunohistochemical staining. As for the cross sectional area of atherosclerotic plaques within aorta, there was no significant difference among all drug treated group compared with control group (P>0.05).
2.3.3 Atherosclerotic plaque composition
As for extracellular lipids area, compared with control group, No.5 and No.7 group had a marked increase (P<0.05), the other groups and atrovastatin group had no significant difference. As for foam cell area, compared with control group, there was no significant difference among all groups (P>0.05). As for the collagen area, compared with control group, No.3 group, No.4 group, No.6 group, No.7 group, No.8 group, and atorvastatin goup was associated with a significant increase (P<0.05). As for the smooth muscle cell area, compared with control group, No.1 group, No.2 group, No.3 group, No.4 group, No.8 group, and atorvastatin group was associated with a significant increase (P>0.05).
2.3.4 Expression of PPAR-γin the aortic plaque
Compared with the control group, No.2 group, No.3 group, No.4 group, No.6 group, No.7 group, No.8 group, and atorvastatin group was associated with a a marked increase in expression of PPAR-y (P<0.05).
2.3.5 Plasma lipid levels
Compared with controls, there was no statistically difference among all drug treated group (P>0.05) in the level of TC, TG, LDL and HDL respectively.
2.3.6 Evaluation of plaque stability
Compared with the control group, No.1 group, No.3 group, No.4 group, No.6 group, No.7 group, No.8 group, and atorvastatin group was associated with a significant reduction in the vulnerability index (Ⅵ) (P<0.05). And the vulnerability index of No.8 group was minimal (P<0.01).
2.3.7 Optimized combination and proportion of Chinese herbs
Taking the vulnerability index as the screen index and multivariant regression analysis of uniform design, we got the optimized combination and proportion of Chinese herbs. The first optimized combination:giant knotweed rhizome 0.3604g, snakegourd fruit 0.3604g, polygonum multiflorum 0.1834g. The second optimized combination:giant knotweed rhizome 0.3604g, polygonum multiflorum 0.1606g.
2.4 Conclusion
The Chinese medicine compound prescription (giant knotweed rhizome, panax pseudo-ginseng, snakegourd fruit, and polygonum multiflorum) had a reduction in the vulnerability index (VI) in ApoE-/- mice which indicated the Chinese medicine compound prescription had potential effect on stabilizing atherosclerotic plaque. By the multivariant regression method, the optimized combination and proportion which could stabilize the atherosclerotic plaque were that the first optimized combination: giant knotweed rhizome 0.3604g, snakegourd fruit 0.3604g, polygonum multiflorum 0.1834g; the second optimized combination:giant knotweed rhizome 0.3604g, polygonum multiflorum 0.1606g, which laid a foundation of the optimized combination verificafion.
引文
[1]李建军.炎症在动脉硬化中的应用.中华心血管杂志,2008,36(3)：93.
[2]王东升,袁肇凯,陈方平.动脉粥样硬化“痰瘀”病理的理论探讨.湖南中医学院学报,2004,24(5)：27-29.
[3]朱明,陆曙.动脉粥样硬化中医病机探讨.陕西中医,2007,28(12)：1055。
[4]周仲英,金妙文.滋肾养肝化痰消瘀法治疗动脉粥样硬化的理论探讨.南京中医药大学学报(自然科学版),2002,18(3)：137-139.
[5]第五永长,肖颖,王友民.动脉粥样硬化中医病机探析.陕西中医学院学报,2003,26(6)：8-10.
[6]于俊生,陈兆昌.动脉粥样硬化从痰疲毒论治探讨.山东中医杂志,2002,21(8)：451-454.
[7]张京春,陈可冀,张文高,等.不稳定斑块的中西医结合认识现状及研究思路.中国中西医结合杂志,2005,25(10)：869-871.
[8]周明学,徐浩,陈可冀.中医脂毒、瘀毒与易损斑块关系的理论探讨.中国中医基础医学杂志,2007,13(10)：737-738.
[9]Rhule A, Navarro S, Smith JR, et al. Panax notoginseng attenuates LPS-induced pro-inflammatory mediators in RAW264.7 cells. J Ethnopharmacol,2006,106 (1): 121-128.
[10]贾乙,李晓辉.炎症因素在泡沫细胞形成中的作用及三七皂苷对其影响.第三 军医大学学报,2005,27(10)：972-974.
[11]吕志军,梁绪国.三七总皂苷对血管内皮细胞凋亡及凋亡调控基因的影响.中西医结合心脑血管病杂志,2005,3(11)：975-977.
[12]闫彦芳,张壮,孙塑伦,等.三七总皂苷及其成分对血管内皮细胞缺氧损伤的保护作用.中国实验方剂学杂志,2002,8(1)：34-37.
[13]曾桂凤,刘建勋,李澎,等.丹参三七不同配比对缺氧复氧损伤人脐静脉内皮细胞的保护作用.精细化工,2006,23(2)：126-129.
[14]何雪峰,李晓辉,李淑惠,等.三七总皂苷对家兔实验性动脉粥样硬化的预防作用.中国药房,2007,18(6)：408-409.
[15]李韬,曲德英,雷菠,等.三七粉对家兔实验性动脉粥样硬化的影响.中医研究,2006,19(1)：17-19.
[16]文川,徐浩,黄启福,等.活血中药对ApoE基因缺陷小鼠血脂及动脉粥样硬化斑块炎症反应的影响.中国中西医结合杂志,2005,25(4)：345-349.
[17]庞荣清,潘兴华,吴亚玲,等.三七总皂苷对兔血管平滑肌细胞核因子kappaB和细胞周期的影响.中国微循环,2004,8(3)：154-156.
[18]Zhang HS, Wang SQ. Notoginsenoside R1 inhibits TNF-a-induced fibronectin production in smooth muscle cells via the ROS/ERK pathway. Free Radic Biol Med, 2006,40(9):1664-1674.
[19]Zhang HS, Wang SQ. Notoginsenoside R1 from Panax notoginseng inhibits TNF-a-induced PAI-1 production in human aortic smooth muscle cells.Vascull Pharmacol,2006,44(4):224-230.
[20]袁志兵,李晓辉,李淑慧,等.三七总皂苷对动脉粥样硬化斑块稳定性的影响.中国天然药物,2006,4(1)：62-65.
[21]袁志兵,李晓辉,李淑惠,等.三七总皂苷改善动脉粥样硬化斑块稳定性的机制探讨.中草药,2006,37(5)：741-743.
[22]彭利晖,冯其海,黄文.络泰对血瘀证患者氧自由基损伤的影响.云南中医学院学报,2004,27(3)：35.
[23]罗尧岳,周小青,谢小兵,等.活血化瘀类方对动脉粥样硬化家兔血脂、血液流变学变化的影响.湖南中医学院学报,2003,23(1)：9.
[24]杜先华,杨芳炬,龚应霞,等.丹参对过氧化氢诱导的大鼠血管平滑肌细胞迁移的影响研究.中医药学刊,2003,21(1)：124.
[25]鞠镐,程文立,董晞.丹参粉针剂对氧化低密度脂蛋白诱导的内皮细胞表达MMMP9及ICAM-1的影响.中日友好医院学报,2005,19(4)：230.
[26]熊涛,吴兴军,王逸平.丹参多酚酸盐抑制低密度脂蛋白氧化修饰.中药药理与临床,2004,20(4)：7-8.
[27]唐利龙,汪丽惠.川芎嗪和肝素对原代培养血管平滑肌细胞生长和分裂的影响.中国中西医结合杂志,1995,15(1)：38.
[28]胡发明,胡红丁.川芎嗪的实验研究及临床应用.中医研究,2004,17(3)：57.
[29]梅家俊,蔡大勇,赵婷秀,等.川芎防治动脉粥样硬化症机制的实验研究.湖北中医学院学报,2004,6(2)：5-9.
[30]丁志山,沃兴德.姜黄降血脂抗动脉粥样硬化研究概况.浙江中医学院学报,1998,22(6)：8.
[31]丁奇峰,陈志强,黄怀鹏,等.姜黄素对大鼠动脉粥样硬化内皮细胞损伤的影响.中药药理与临床,2005,21(5)：10-11.
[32]盛柳青,颜继忠,梁万根.姜黄素的研究进展及应用概况.中国西部科技,2006,4：14.
[33]戴敏,訾晓梅,彭代银,等.丹皮酚抗鹌鹑实验性动脉粥样硬化作用.中国中药杂志,1999,24(8)：488.
[34]刘晓颖,李凤文,张立石,等.水蛭对实验性动脉粥样硬化家兔血管内皮功能障碍的影响.中国中医基础医学杂志,1998,4(3)：15.
[35]李凤文,张立石,刘红,等.水蛭、丹参及其复方对血瘀大鼠血管内皮细胞保护作用的研究.中国中药杂志,2001,26(10)：703.
[36]郑占虎.中药现代研究与应用.北京：学苑出版社,1998.4435-4437.
[37]唐绪刚,黄文权,姜利鲲.中药五灵脂对动脉粥样硬化大鼠细胞问黏附分子-1的影响.中国老年学杂志,2008,28(12)：2318-2321.
[38]Li J B, Lin M. Studies on the chemical constituents of Poly-gonum multiflorum. Chin Tradit Herb Drugs,1993,24(3):115-118.
[39]宋士军,李芳芳,尹智玮,等.何首乌对实验性高脂血症作用的研究.河北中医 药学报,2003.18(4)：27-28.
[40]张伟,李锋,王玉琴,等.二苯乙烯苷对实验性动脉粥样硬化大鼠血脂和炎症因子的调节作用.中国临床药理学与治疗学,2007,12(5)：516-520.
[41]张伟,王春华,沈燕,等.二苯乙烯苷对实验性大鼠动脉粥样硬化的治疗作用.中国药科大学学报,2007,38(3)：261-264.
[42]高瑄,胡英杰,符林春.何首乌二苯乙烯苷的调节血脂作用.中国中药杂志,2007,32(4)：323-326.
[43]Shanhong Ling, Lina Nheu, Aozhi Dai, et al. Effects of four medicinal herbs on human vascular endothelial cells in culture. International Journal of Cardiology, 2008,128:350-358.
[44]王旻晨,吴开云,杨亚安.何首乌提取物对内皮细胞T-AOC、LPO、NO、SOD代谢的影响.中国现代医药杂志,2005,7(1)：34-36.
[45]方微,张慧信,王绿娅,等.何首乌总甙抗氧化与实验性小鼠主动脉粥样硬化病变的形成.中国中药杂志，2007,32(13)：1320-1323.
[46]Zhang W, Wang CH, Li F, et al.2,3,4',5-Tetrahydroxysti-1bene-2-O-beta-D-glucoside suppresses matrix metalloproteinase expression and inflammation in atherosclerotic rats. Clin Exp Pharmacol Physiol,2008,35(3):310-6.
[47]张伟,王春华,李锋.二苯乙烯苷对大鼠动脉硬化模型的MMP-2、9表达的影响.中国临床药理学杂志,2008,24(2)：134-138.
[48]Liu QL, Xiao JH, Ma R, et al. Effect of 2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside on lipoprotein oxidation and proliferation of coronary arterial smooth cells. Journal of Asian Natural Products Research,2007,9(8):689-697.
[49]汪德清,丁保国,Tomas G Neil,等.黄芪总黄酮对动脉粥样硬化早期形成的影响.中国药理学通报,2003,19(6)：637.
[50]杨五彪,陈群力,马灵筠,等.黄芪多糖对兔动脉粥样硬化血管内皮细胞功能的影响.陕西医学杂志,2005,34(8)：914-918.
[51]杨五彪,陈群力,马灵筠,等.黄芪多糖对兔动脉粥样硬化内皮素-1、C反应蛋白的影响.中华实用中西医杂志,2005,14(18)：317-319.
[52]张馨木,曲绍春,睢大员,等.人参Rb组皂苷对高脂血症大鼠血脂代谢的影响 及其抗氧化作用.中国中药杂志,2004,29(11)：1085-1088.
[53]赵艳威,于小风,徐华丽,等.人参果皂苷注射液对高脂血症大鼠血脂代谢的影响.吉林大学学报(医学),2005,31(3)：407-410.
[54]曲绍春,睢诚,于晓风,等.人参Rb组皂苷对大鼠实验性心肌缺血再灌注损伤的保护作用.吉林大学学报,2007,33(5)：849-852.
[55]防方,段胜仲.绞股蓝总皂甙对培养兔血.管平滑肌细胞基因表达的影响.湖北医科大学学报,1997,18(4)：297-299.
[56］许士凯,何红.绞股蓝总皂甙对氧化修饰低密度脂蛋白损伤小牛主动脉内皮细胞的防治作用,中国临床药理学与治疗学,2002,7(5)：389-340.
[57]李峰,刘小滨,卢银让,等.绞股蓝饮料降血脂功能.试验毒理学杂志,2006,20(4)：274.
[58]谭华炳,匡颖文.绞股蓝干预食饵兔动脉粥样硬化过程中对内皮素-1和C反应蛋白的影响研究.山西医药杂志,2006,35(10)：866-868.
[59]Hou YZ, Zhao GR, Yang J, et al. Protective effect of ligusticum chuanxiong and angelica sinensis on endothelial cell damage induced by hydrogen peroxide. Life Sci,2004,75(14):1775-1786.
[60]马渝,史若飞,文玉明等.虎杖抗动脉粥样硬化作用的实验研究.中国中医急症,2005,14(6)：564-566.
[61]肖铭甲,陈卫红,吴炜等.虎杖苷抑制ox-LDL诱导的脂质过氧化并下调巨噬细胞清道夫受体CD36表达.中国病理生理杂志,2010,26(7)：1280-1284.
[62]刘龙涛,吴敏,张文高等.虎杖苷对颈动脉粥样硬化斑块稳定性的干预研究.北京中医药,2009,28(3)：172-175.
[63]郑广娟,朱莹,王婷.虎杖配伍山楂抗动脉粥样硬化易损斑块病变的机制研究.中国病理生理杂志,2010,26(4)：635-639.
[64]熊一力,王宏伟.API0134对平滑肌细胞增殖和碱性纤维母细胞生长因子及相关癌基因表达的影响.中国动脉硬化杂志,1997,5(1)：45-47.
[65]王宏伟,赵华月,熊一力.穿心莲提出物对动脉粥样硬化家兔动脉壁PDGF-B、 c-sis和c-myc基因表达的影响.同济医科大学学报,1998,27(1)：46-48.
[66]康丽华,贺卫乎,曹军杰,等.穿心莲黄酮片治疗脑动脉粥样硬化的研究.镇江 医学院学报,2000,10(2)：237.
[67]赵咏梅,李发荣,杨建雄,等.连翘苷降血脂及抗氧化作用的实验研究.天然产物研究与开发：发,2005,17(2)：157-159.
[68]张立伟,刘金,杨频.中草药连翘提取物抗氧化活性研究.食品科学,2003,24(2)：122-125.
[69]贺圣文,赵仁宏,陈景武,等.马齿苋对家兔实验性动脉粥样硬化形成的作用.潍坊医学院学报,2003,25(3)：161.
[70]贺圣文,赵仁宏,吴洪娟,等.野生马齿苋对家兔动脉粥样硬化形成的影响.中华预防医学杂志,1997,31(2)：91.
[71]贺圣文,王春梅,赵仁宏,等.马齿苋抗动脉粥样硬化形成及延缓衰老的实验研究.预防医学文献信息,1996,2(4)：322-323.
[72]余建清.半枝莲总黄酮对红细胞膜脂质过氧化损伤的保护作用.中国药师,2005,8(11)：897.
[73]李瑞峰,温海涛.半边莲不同组分对内皮细胞内皮素及内皮源一氧化氮合酶代谢的影响.中国动脉硬化杂志,2002,10(1)：19.
[74]于永芳,高瑞峰,李沈明.黄芩茎叶总黄酮对动咏粥样硬化早期病理改变的影响.中草药,2003,34(11)：1033-1034.
[75]佟继铭,陈光晖,刘玉玲,等.黄芩茎叶总黄酮对家兔实验性动脉粥样硬化的预防作用.中草药,2005,36(1)：93-94.
[76]文川,徐浩,黄启福,等.活血中药对ApoE基因缺陷小鼠血脂及动脉粥样硬化斑块炎症反应的影响.中国中西医结合杂志,2005,25：345.
[77]李自成,常青,巫少荣.瓜蒌注射液对兔主动脉平滑肌细胞增殖的影响.新中医,2000,32(5)：33-34.
[78]王冬梅,代世元,芦丽莉,等.瓜蒌皮提取物对大鼠动脉粥样硬化保护作用的实验研究.北华大学学报,2008,9(2)：128-131.
[79]王姗姗.瓜萎皮的药理作用及其临床应用.山西医药杂志,2009,38(1)：67.
[80]宋宏雁,班努·库肯.瓜萎皮注射液治疗不稳定型心绞痛疗效观察.现代中西医结合杂志,2009,18(31)：3820-3821.
[81]蒋文跃,杨宇.化痰药半夏、瓜蒌、浙贝母、石菖蒲对大鼠血液流变性的影 响.中医杂志,2002,43(3)：215.
[82]沈雅琴,张明发.半夏的镇痛、抗溃疡和抗血栓形成作用.中国生化药物杂志,1998,19(3)：141.
[83]吉中强,宋鲁卿,牛其昌.十五种理气中药体外对人血小板聚集的影响.中草药,2001,32(5)：428-430.
[84]吉中强,宋鲁卿,高晓析,等.11种中药对大鼠血小板聚集、红细胞血流变性的影响.山东中医杂志,2000,19(2)：107-108.
[85]刘贵京,张华云.山楂对冠心病同型半胱氨酸血症的影响.中国病理生理杂志,2002,18(11)：1332-1333.
[86]刘春丽,张凤林,李明凯,等.山楂提取物对心肌缺血／再灌注损伤的保护作用.心脏杂志,2006,18(2)：127.
[87]王云来,樊守艳,韩进.山楂丹参合用调节血脂作用的实验研究.浙江中医药大学学报,2006,30(5)：468.
[88]郑勇英,杨隽,潘喜华,等.银含叶抗衰老和调节血脂的实验研究.上海预防医学杂志,2000,12(2)：71
[89]陈临溪,王蓉蓉,黄红林,等.银杏叶提取对饲养高胆固醇兔动脉粥样硬化和低密度脂蛋白体外氧化的作用.心肺血管病杂志,2001,20(1)：46.
[90]张荣怀,李源,王晓明,等.银杏黄酮甙对人巨细胞病毒感染促进动脉粥样硬化发生和发展的保护作用.中国临床康复,2004,8(6)：1714-1715.
[91]刘宇,顾仁樾,王逸平.银杏胶囊防治兔动脉粥样硬化的实验研究.中医杂志,2003,44(2)：133-134.
[92]吴兴利,王士雯,徐雅琴.银杏叶提取物对兔血管平滑肌细胞分泌细胞因子的影响.中国新药与临床杂志,2003,22(5)：292-293.
[93]吕燕宁,王伟,张涛,等.葛根素对血管平滑肌细胞凋亡及其相关基因表达的影响.中华临床医药,2002,3(1)：9.
[94]荆涛,王绿娅,王伟,等.葛根素调节血管平滑肌细胞凋亡相关基因在斑块组织中表达的研究.中国药学杂志,2003,38(9)：667-670.
[95]Hong Y, ShaoHuaH, Zi Ren S. Inhibition of Neuropeptide-Y-induced Vascular Smooth Muscle Cell Proliferation with Pueraria Lobata Isoflavone广州中医药大学 学报,2005,22(3)：203.
[96]甄艳军,安杰,周晓红，木贼对动脉粥样硬化早期大鼠血清IL-1、IL-8及TNF-α的影响.中国老年学杂志,2003,23(8)：1714-1715.
[97]甄艳年,安杰,侯建明.木贼对动脉粥样硬化早期大鼠内皮细胞凋亡及Bax、Bcl-2表达的影响.中国老年学杂志,2003,23(5)：305-304.
[98]刘丽梅,高政,李宝文,等.余甘子对实验性颈动脉粥样硬化家兔的影响.中国临床康复,2003,7(5)：766-767.
[99]王素敏,张杰,李兴琴.车前子对高脂血症大鼠机体自由基防御机能的影响.中国老年学杂志,2003,23(8)：529-530.
[100]秦建国,王亚红,梁晋普,等.泽泻萜帖类化合物对ApoE基因敲除动脉粥样硬化小鼠肝脏基底膜HSPG的调节作用.中华中医药学刊,2007,25(4)：696-697.
[101]工亚利,司秋菊,王鑫国,等.蜈蚣对动脉粥样硬化家兔血管平滑肌细胞周期及c-myc基因表达的影响.中药药理与临床,2001,17(6)：28.
[102]王雁萍,魏重琴.酸枣仁皂甙A对血管平滑肌细胞增值及SIS基因表达的影响.心肺血管病杂志,2002,21(1)：43-44.
[1]Valgimigli M, Agostoni P, Serruvs PW. Acute coronary syndromes:an emphasis shift from treatment to prevention, and the enduring challenge of vulnerable plaque detection in the cardiac catheterization laboratory. J Cardiovasc Med(Hagerstown), 2007,8(4):221-229.
[2]王涛,浦艳华,殷洁,等.易损斑块与急性冠咏综合征.心血管病学进展,2007,28(2)：246-248.
[3]Lerakis S, Synetos A, Toutouzas K, et al. Imaging of the vulnerable plaque: Noninvasive and Invasive techniques. Am J Med Sci,2008,336(4):342-348.
[4]Achenbach S, Moselewski F, Ropers D, et al. Detection of calcified and noncalcified coronary atherosclerotic plaque by contrast-enhanced, bmillimeter multidetector spiral computed tomography: a segment-based comparison with intravascular ultrasound. Circulation,2004,109(1):14-17.
[5]Leber AW, Knez A, Becker A, et al. Accuracy of multidetector spiral computed tomography in identifying and differentiating the composition of coronary atherosclerotic plaques:a comparative study with intracoronary ultrasound. J Am Coll Cardiol,2004,43(7):1241-1247.
[6]Caussin C, Ohanessian A, Ghostine S, et al. Characterization of vulnerable nonstenotic plaque with 16-slice computed tomography compared with intravascular ultrasound. Am J Cardiol,2004,94(1):99-104.
[7]Viles-Gonzalez JF, Poon M, Sanz J, et al. In vivo 16-slice, multidetector-row computed tomography for the assessment of experimental atherosclerosis: comparison with magnetic resonance imaging and histopathology. Circulation,2004, 110(11):1467-1472.
[8]Inoue F, Sato Y, Matsumoto N, et al. Evaluation of plaque texture by means of multislice computed tomography in patients with acute coronary syndrome and stable angina. Circulation,2004,110:1467-1472.
[9]Moselewski F, Ropers D, Pohle K, et al. Comparsion of measurement of cross-sectional coronary atherosclerotic plaque and fessel areas by 16-slice multidetector computed tomography versus intravascular ultrasond. Am J Cardiol, 2004,94:1294-1297.
[10]Leber AW, Knez A, von Ziegler F, et al. Quantification of obstructive and nonobstructive coronary lesions by 64-slice computed tomography:a comparative study with quantitative coronary angiography and intravascular ultrasound. J Am Coll Cardio,2005,46:147-154.
[11]Leschka S, Scheffel H, Desbiolles L, et al. Image quality and reconstruction intervals of dual-source CT coronary angiography:recommendations for ECG-pulsing windowing. In vest Radiol,2007,42:543-549.
[12]Schroeder S, Kuettner A, Leitritz M, et al. Reliability of differentiating human coronary plaque morphology using contrast-enhanced multislice spiral computed tomography:a comparison with histology. J Comput Assist Tomogr,2004,28: 449-454.
[13]Yuan C, Mitsumori LM, Beach KW, et al. Carotid atherosclerotic plaque: noninvasive MR characterization and identification of vulnerable lesions. Radiolgy, 2001,221:285-299.
[14]Wilensky RL, Song HK, Ferrari VA. Role of magnetic resonance and intravascular magnetic resonance in the detection of vulnerable plaques. J Am Coll Cardiol,2006,47(suppl 8):C48-C56.
[15]Hatsukami TS, Rose R, Polissar NL, et al. Visualization of fibrous cap thickness and rupture in human atherosclerotic carotid plaque in vivo with high-resolution magnetic resonance imaging. Circulation,2000,102:959-964.
[16]Trivedi RA, Mallawarachi C, U-King-Im JM, et al. Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler Thromb Vase Biol,2006,26:1601-1606.
[17]Ruehm SG, Corot C, Vogt P, et al. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation,2001,103:415-422.
[18]Sirol M, Itskovich VV, Mani V, et al. Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. Circulation,2001, 103:1601-1606
[19]Steen H, Warren WP, Desai M, et al. Combined transesophageal and surface MRI provides optimal imaging in aortic atherosclerosis. J Cardiovasc Magn Reson, 2004,6:909-916.
[20]Ohtsuki K, Hayase M, Akashi K, et al. Detection of monocyte chemoattractant protein-1 receptor expression in experimental atherosclerotic lesions:an autoradiographic study. Circulation,2001,104(2):203-208.
[21]Iuliano L, Signore A, Vallabajosula S, et al. Preparation and bio-distribution of 99m technetium labeled oxidized LDL in man. Atherosclerosis,1996,126(1): 131-141.
[22]Kopka K, Breyholz HJ, Wagner S, et al. Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo. Nucl Med Biol,2004,31(2):257-267.
[23]Kolodgie FD, Edwards S, Petrov A, et al, Noninvasive detection of matrix metalloproteinase upregulation in experimental atherosclerotic lesions and its abrogation by dietary modification (abstr). Circulation,2001,104(6):694.
[24]Kolodgie FD, Petrov A, Virmani R, et al. Targeting of apoptotic macrophages and experimental atheroma with radiolabeled annexin V: a technique with potential for noninvasive imaging of vulnerable plaque. Circulation,2003,108(25): 3134-3139.
[25]Zhao QM, Xu JP, Wang Q, et al. Noninvasive imaging of vulnerable plaque with radio labeled annexin V: expetimental study. Chin J Med Imaging Technol, 2005,21(9):1349-1352.
[26]Vallabojosula S, Machac K, Knesaurek J. Imaging atherosclerotic macrophage density by positron emission tomography using F-18 fluorodeoxyglucose (FDG). J Nucl Med,1996,37(Suppl 1):38.
[27]Rudd JII, Warburton EA, Fryer TD, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation,2002,105(23):2708-2711.
[28]Kotani J, Mintz GS, Castagna MT, et al. Intravascular ultrasound analysis of infarct-related and non-infarct-related arteries in patients who presented with an acute myocardial infarction. Circulation 2003; 107:2889-2893.
[29]von Birgelen C, Klinkhart W, Mintz GS, et al. Plaque distribution and vascular remodeling of ruptured and nonruptured coronary plaques in the same vessel:an intravascular ultrasound study in vivo. J Am Coll Cardiol,2001,37:1864-1870.
[30]Ehara S, Kobayashi Y, Yoshiyama M, et al. Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction:an intravascular ultrasound study. Circulation,2004,10(22):3424-3429.
[31]Maddux JT, Wink O, Messenger JC, et al. Randomized study of the safety and clinical utility of rotational angiography versus standard angiography in the diagnosis of coronary artery disease. Catheter Cardiovasc Interv,2004,62:164-174.
[32]Chen SJ, Carroll JD.3-D reconstruction of coronary arterial tree to optimize angiographic visualization. IEEE Trans Med Imaging,2000,19(4):318-336.
[33]Beckman JA, Ganz J, Creager MA, et a.l Relationship of clinical presentation and calcification of culprit coronary artery stenoses. Arterioscler Thromb Vasc Bio,1 2001,21 (10):1618-1622.
[34]Virmani R,Burke AP, Kolodgie FD, et al. Pathology of the thin-cap fibroatheroma:A type of vulnerable plaque. J Interv Cardiol,2003,16(3):267-272.
[35]De Korte CL. Intravascular ultrasound elastography: An overview. Ultrasonics, 2002,40:859-865.
[36]Schaar JA, De Korte CL, Mastik F, et al. Characterizing vulnerable plaque features with intravascular elastography. Circulation,2003,108:2636-2641.
[37]Komiyama N, Berry GJ, Kolz ML, et al. Tissue characterization of atherosclerotic plaques by intravascular ultrasound radiofrequency signal analysis: an in vitro study of human coronary arteries. Am Heart J,2000,140(4):565-574.
[38]Carlier S, Kakadiaris IA, Dib N, et al. Vasa vasorum imaging:A new window to the clinical detection of vulnerable atherosclerotic plaques. Curr Athero Rep,2005,7 (2):164-169.
[39]Stamper D, Weissman NJ, Brezinski M. Plaque characterization with optical coherence tomography. J Am Coll Cardiol 2006; 47(Supp18):C69-C79.
[40]Fujimoto JG, Boppart SA, Tearney GJ, et al. High resolution in vivo intra-arterial imaging with optical coherence tomography. Heart,1999,82:128-133.
[41]Brezinski M. Characterizing arterial plaque with optical coherence tomography. Curr Opin Cardiol,2002,17:648-655.
[42]Patel NA, Stamper DL, Brezinski ME. Review of the ability of optical coherence tomography to characterize plaque, including a comparison with intravascular ultrasound. Cardiovasc Intervent Radiol,2005.28:1-9.
[43]Bouma BE, Tearney GJ, Yabushita H, et al. Evaluation of intracoronary stenting by intravascular optical coherence tomography. Heart,2003,89(3): 317-320.
[44]Tearney GJ, Brezinski ME, Bouma BE, et al. In vivo endoscopic optical biopsy with optical coherence tomography. Science,1997,276(5321):2037-2039.
[45]Tearney GJ, Brezinski ME, Boppart SA, et al. Images in cardiovascular medicine. Catheter-based optical imaging of a human coronary artery. Circulation, 1996,94(11):3013.
[46]Mizuno K, Miyamoto A, Satomura K, et al. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. Lancet,1991,337:586-589.
[47]Miyamoto A, Prieto AR, Friedl SE, et al. Atheromatous plaque cap thickness can be determined by quantitative color analysis during angioscopy:implications for identifying the vulnerable plaque. Clin Cardiol,2004,27(1):9-15.
[48]Takano M, Mizuno K, Yokoyama S, et al. Changes in coronary plaque color and morphology by lipid-lowering therapy with atorvastatin:serial evaluation by coronary angioscopy. J Am Coll Cardiol,2003,42(4):680-686.
[49]Casscella W, Hathorn B, David M, et al. Thermal detection of celluar infiltrates in living atherosclerotic plaques:possible implica-tions for plaque rupture and thrombosis [J].Lancet,1996,347:1447-1449.
[50]Stefanadis C, Diamantopoulos L. Vlacho-poulos C, et al. Thermal heterogeneity within human atherosclerotic coronary arteries detected in vivo. A new method of detection by application of a special thermography catheter. Circulation,1999,99: 1965-1971.
[51]Fayad ZA, Fuster V. Clinical imaging of the high-risk or vulnerable atherosclerotic plaque. Circ Res,2001,89:305-316.
[52]Toutouzas K, Synetos A, Stefanadi E, et al. Correlation between morphologic characteristics and local temperature differences in culprit lesions of patients with symptomatic coronary artery disease. J Am Coll Cardiol,2007,49(23):2264-2271.
[53]Naghavi M, John R, Naguib S, et al. PH Heterogeneity of human and rabbit atherosclerotic plaques; a new insight into detection of vulnerable plaque. Atherosclerosis,2002,164:27-35.
[54]Khan, De Meyer GR, Van langenhove G, et al. In vivo temperature heterogeneity of atherosclerotic plaques in determined by plaque composition. Circulation,2002,105:1596-1601.
[55]Brennan JF Ⅲ, Romer TJ, Lees RS, et al. Histopathology of human coronary atherosclerosis by quantifying its chemical composition with Raman spectroscopy. Circulation,1998,97(9):878-885.
[56]Moreno PR, Lodder RA, Purushothaman KR, et al. Detection of lipid pool, thin fibrous cap, and inflammatory cells in human aortic atherosclerotic plaques by near-infrared spectroscopy. Circulation,2002,105(8):923-927.
[57]Hamdan A, Assali A, Fuchs S, et al. Imaging of vulnerable coronary artery plaques. Catheter Cardiovasc Interv,2007,70(1):65-74.
[58]Quick HH, Ladd ME, Hilfiker PR, et al. Autoperfused balloon catheter for intravascular MR imaging. J Magn Reson Imaging,1999,9(3):428-434.
[59]Worthley SG, Helft G, Fuster V, et al. A novel nonobstructive intravascular MRI coil:in vivo imaging of experimental atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology,2003,23(2):346-350.
[1]Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation,1979,59:607-609.
[2]中国中西医结合学会心血管专业委员会.冠心病中医辨证标准.中西医结合杂志,1991,11(5)：257.
[3]田德禄主编.中医内科学(第7版).北京：人民卫生出版社,2006.
[4]郭志华.冠心病心绞痛2432例中医辨证分型综合统计分析.湖南中医杂志,1998,14(2)：7-8.
[5]张琳,于鑫婷,徐浩.冠心病中医证候特点的分析与思考.中西医结合心脑血管病杂志,2009,7(5)：578-581.
[6]高铸烨,张京春,徐浩,等.用复杂网络挖掘分析冠心病证候-治法-中药关系.中西医结合学报,2010,8(3)：238-243.
[7]付长庚,高铸烨,陈静,等.京津地区冠心病证候-治法-方药的现况调查.中国实验方剂学杂志,2010,16(12)：176-179.
[8]]王雪华,夏春明,颜建军,等.中医证候分类中常用多元统计分析方法及应用评析.世界科学技术-中医药现代化思路与方法,2008,10(2)：15-20.
[9]王阶,何庆勇,李海霞,等.815例不稳定型心绞痛中医证候的因子分析.中西医结合学报,2008,8(6)：788-792.
[10]张晓东.温阳养阴法治疗不稳定性心绞痛的理论探讨及实验研究.南京中医药大学优秀硕士毕业论文集,2005.
[11]王瑞科,杨继平,李红.葛丹稳心汤对不稳定性心绞痛患者LPA影响的临床研究.湖南中医杂志,2007,23(2)：5-7.
[12]刘耀乾,李小苹.丹参滴丸和川芎嗪配合西药联合治疗不稳定型心绞痛临床观察.中国中西医结合杂志,2003,23(7)：544-545.
[13]徐浩,史大卓,殷惠军,等.“瘀毒致变”与急性心血管事件：假说的提出与临床意义.中国中西医结合杂志,2008,28(10)：934-938.
[1]Naghavi M, Libby P, Falk E, et al. From vulnerable Plaque to vulnerable Patient: a call for new definition and risk assessment strategies:Part Ⅰ. Circulation.2003, 108(14):1664-1672.
[2]Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med,1999; 340(2): 115-126.
[3]Hansson GK. Immune mechanism in atherosclerosis. Arteroscler Thromb Vasc Biol,2001; 21:1876-1890.
[4]徐浩,史大卓,殷惠军,等.“瘀毒致变”与急性心血管事件：假说的提出与临床意义.中国中西医结合杂志,2008,28(10)：934-938.
[5]文川,徐浩,黄启福,等.几种活血中药对ApoE缺陷小鼠动脉粥样硬化斑块影 响的形态学研究.中国病理生理杂志,2005,21(8)：864-867.
[6]周明学,徐浩,陈可冀,等.活血解毒中药有效部位对ApoE基因敲除小鼠动脉粥样斑块稳定性的影响.中国病理生生理杂志,2008,17(6)：588-591.
[7]Johnson J, Carson K, Williams H, et al. Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse:model characterization and effeets of pravastatin treatment. Circulation,2005,111(23):1422-1430.
[8]许淑云,卞如濂,陈修.药理实验方法学.第3版.北京：人民卫生出版社,2002：202-204.
[9]Suzuki H, Kurihara Y, Takeya M, et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature,1997,386(6622): 292-296.
[10]李莉,翟同均,陈融,等Movat五色套染法的改进及应用.临床与实验病理学志,2002,18(6)：660-662.
[11]Masashi S, Takashi I, Yasuhiko H, et al. Fibromuseular cap composition is important for the stability of established atheroselerotic plaques immature WHHL rabbits treated with statins. Atherosclerosis,2001,157(1):75-84.
[12]Johnson JL, Fritsche DR, Behrendt M, et al. Effect of broadspectrum matrix metalloproteinase inhibition on athero sclerotic plaque stability. Cardiovasc Res, 2006,71(4):586-595.
[13]张京春,陈可冀.瘀毒病机与动脉粥样硬化易损斑块相关的理论思考.中国中西医结合杂志,2008,28(4)：366-368.
[14]周明学,徐浩,陈可冀.中医脂毒、瘀毒与易损斑块关系的理论探讨.中国中医基础医学杂志,2007,13(10)：737-738.
[15]于俊生,陈兆昌.动脉粥样硬化从痰瘀毒论治探讨.山东中医杂志,2002,21(8)：451-453.
[16]卢笑辉.论热毒在急性冠脉综合征发病中的作用.中国中医急症,2005,14(8)：750-751.
[17]徐浩,文川,陈可冀,等.川芎、赤芍及其有效部位配伍对载脂蛋白E基因缺陷小鼠动脉粥样硬化斑块稳定性影响的研究.中国中西医结合杂志,2007,27(6)：513-518.
[18]张京春,陈可冀,刘剑刚,等.解毒活血配伍方药对载脂蛋白E基因敲除小鼠血清超敏C反应蛋白的影响.中国中西医结合杂志,2008,28(4)：330-333.
[19]张京春,陈可冀,郑广娟,等.解毒活血中药配伍对载脂蛋白E基因敲除小鼠主动脉NF-κB和MMP-9表达的调控作用.中国中西医结合杂志,2007,27(1)：40-44.
[20]刘剑刚,董国菊,史大卓,等.气血并治方提取物对ApoE基因缺陷小鼠动脉粥样硬化病理形态和基质金属蛋白酶-1及其抑制物表达的影响.中国药学杂志,2008,43(22)：1700-1705.
[21]刘运芳,赵玉霞,于会明,等.祛瘀消斑胶囊对实验性动脉粥样硬化斑块组织学构成的影响.上海中医药大学学报,2005,19(3)：34-35.
[22]常章富.中药学.北京：中国医药出版社,2001：108.
[23]张京春.解毒活血干预动脉粥样硬化易损斑块的综合研究.山东中医药大学博士毕业论文,2007.
[24]孙小玲.三七的研究进展.云南中医中药杂志,2005,26(6)：44-46.
[25]腾勇荣,张永清.瓜蒌化学成分研究进展.山东中医药大学学报,2011,35(1)：85-86.
[26]腾勇荣,王连侠.张水清.瓜蒌药理研究进展.齐鲁药事,2010,29(7)：417-418.
[27]彭晓波.何首乌的研究和应用.中国现代药物应用,2008,2(19)：117.
[28]周明学,徐浩.陈可冀,等.活血解毒中药有效部位对ApoE基因敲除小鼠血脂和动脉粥样硬化斑块炎症反应的影响.中国中西医结合杂志,2008,28(2)：126-130.
[29]文川,徐浩,黄启福,等.活血中药对ApoE基因缺陷小鼠血脂及动脉粥样硬化斑块炎症反映的影响.中国中西医结合杂志,2005,25(4)：345-349.
[30]周明学,徐浩,潘琳,等.活血、益气、化痰中药对ApoE基因敲除小鼠主动脉粥样硬化斑块炎症反应的影响.中国中医急症,2008,17(4)：496-498.
[31]曾昭均主编.均匀设计及其应用.沈阳：辽宁人民出版社,1994：5.
[32]Zaman AG, Helft G, Worthley SG, et al. The role of Plaque rupture and thrombosis in coronary artery disease. Atheroselerosis,2000,149:251-266.
[33]Giroud D, Li JM, Urban P, et al. Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiograPhy. Am J Cardiol,1992,69:729-732.
[34]Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol,1988,12:56-62.
[35]Jiang C, Ting AT, Seed B. PPAR yagonists inhibit production of monocyte inflammatory cytokines. Nature,1998,391(6662):82-86.
[2]王东升,袁肇凯,陈方平.动脉粥样硬化“痰瘀”病理的理论探讨.湖南中医学院学报,2004,24(5)：27-29.
[3]朱明,陆曙.动脉粥样硬化中医病机探讨.陕西中医,2007,28(12)：1055。
[4]周仲英,金妙文.滋肾养肝化痰消瘀法治疗动脉粥样硬化的理论探讨.南京中医药大学学报(自然科学版),2002,18(3)：137-139.
[5]第五永长,肖颖,王友民.动脉粥样硬化中医病机探析.陕西中医学院学报,2003,26(6)：8-10.
[6]于俊生,陈兆昌.动脉粥样硬化从痰疲毒论治探讨.山东中医杂志,2002,21(8)：451-454.
[7]张京春,陈可冀,张文高,等.不稳定斑块的中西医结合认识现状及研究思路.中国中西医结合杂志,2005,25(10)：869-871.
[8]周明学,徐浩,陈可冀.中医脂毒、瘀毒与易损斑块关系的理论探讨.中国中医基础医学杂志,2007,13(10)：737-738.
[9]Rhule A, Navarro S, Smith JR, et al. Panax notoginseng attenuates LPS-induced pro-inflammatory mediators in RAW264.7 cells. J Ethnopharmacol,2006,106 (1): 121-128.
[10]贾乙,李晓辉.炎症因素在泡沫细胞形成中的作用及三七皂苷对其影响.第三 军医大学学报,2005,27(10)：972-974.
[11]吕志军,梁绪国.三七总皂苷对血管内皮细胞凋亡及凋亡调控基因的影响.中西医结合心脑血管病杂志,2005,3(11)：975-977.
[12]闫彦芳,张壮,孙塑伦,等.三七总皂苷及其成分对血管内皮细胞缺氧损伤的保护作用.中国实验方剂学杂志,2002,8(1)：34-37.
[13]曾桂凤,刘建勋,李澎,等.丹参三七不同配比对缺氧复氧损伤人脐静脉内皮细胞的保护作用.精细化工,2006,23(2)：126-129.
[14]何雪峰,李晓辉,李淑惠,等.三七总皂苷对家兔实验性动脉粥样硬化的预防作用.中国药房,2007,18(6)：408-409.
[15]李韬,曲德英,雷菠,等.三七粉对家兔实验性动脉粥样硬化的影响.中医研究,2006,19(1)：17-19.
[16]文川,徐浩,黄启福,等.活血中药对ApoE基因缺陷小鼠血脂及动脉粥样硬化斑块炎症反应的影响.中国中西医结合杂志,2005,25(4)：345-349.
[17]庞荣清,潘兴华,吴亚玲,等.三七总皂苷对兔血管平滑肌细胞核因子kappaB和细胞周期的影响.中国微循环,2004,8(3)：154-156.
[18]Zhang HS, Wang SQ. Notoginsenoside R1 inhibits TNF-a-induced fibronectin production in smooth muscle cells via the ROS/ERK pathway. Free Radic Biol Med, 2006,40(9):1664-1674.
[19]Zhang HS, Wang SQ. Notoginsenoside R1 from Panax notoginseng inhibits TNF-a-induced PAI-1 production in human aortic smooth muscle cells.Vascull Pharmacol,2006,44(4):224-230.
[20]袁志兵,李晓辉,李淑慧,等.三七总皂苷对动脉粥样硬化斑块稳定性的影响.中国天然药物,2006,4(1)：62-65.
[21]袁志兵,李晓辉,李淑惠,等.三七总皂苷改善动脉粥样硬化斑块稳定性的机制探讨.中草药,2006,37(5)：741-743.
[22]彭利晖,冯其海,黄文.络泰对血瘀证患者氧自由基损伤的影响.云南中医学院学报,2004,27(3)：35.
[23]罗尧岳,周小青,谢小兵,等.活血化瘀类方对动脉粥样硬化家兔血脂、血液流变学变化的影响.湖南中医学院学报,2003,23(1)：9.
[24]杜先华,杨芳炬,龚应霞,等.丹参对过氧化氢诱导的大鼠血管平滑肌细胞迁移的影响研究.中医药学刊,2003,21(1)：124.
[25]鞠镐,程文立,董晞.丹参粉针剂对氧化低密度脂蛋白诱导的内皮细胞表达MMMP9及ICAM-1的影响.中日友好医院学报,2005,19(4)：230.
[26]熊涛,吴兴军,王逸平.丹参多酚酸盐抑制低密度脂蛋白氧化修饰.中药药理与临床,2004,20(4)：7-8.
[27]唐利龙,汪丽惠.川芎嗪和肝素对原代培养血管平滑肌细胞生长和分裂的影响.中国中西医结合杂志,1995,15(1)：38.
[28]胡发明,胡红丁.川芎嗪的实验研究及临床应用.中医研究,2004,17(3)：57.
[29]梅家俊,蔡大勇,赵婷秀,等.川芎防治动脉粥样硬化症机制的实验研究.湖北中医学院学报,2004,6(2)：5-9.
[30]丁志山,沃兴德.姜黄降血脂抗动脉粥样硬化研究概况.浙江中医学院学报,1998,22(6)：8.
[31]丁奇峰,陈志强,黄怀鹏,等.姜黄素对大鼠动脉粥样硬化内皮细胞损伤的影响.中药药理与临床,2005,21(5)：10-11.
[32]盛柳青,颜继忠,梁万根.姜黄素的研究进展及应用概况.中国西部科技,2006,4：14.
[33]戴敏,訾晓梅,彭代银,等.丹皮酚抗鹌鹑实验性动脉粥样硬化作用.中国中药杂志,1999,24(8)：488.
[34]刘晓颖,李凤文,张立石,等.水蛭对实验性动脉粥样硬化家兔血管内皮功能障碍的影响.中国中医基础医学杂志,1998,4(3)：15.
[35]李凤文,张立石,刘红,等.水蛭、丹参及其复方对血瘀大鼠血管内皮细胞保护作用的研究.中国中药杂志,2001,26(10)：703.
[36]郑占虎.中药现代研究与应用.北京：学苑出版社,1998.4435-4437.
[37]唐绪刚,黄文权,姜利鲲.中药五灵脂对动脉粥样硬化大鼠细胞问黏附分子-1的影响.中国老年学杂志,2008,28(12)：2318-2321.
[38]Li J B, Lin M. Studies on the chemical constituents of Poly-gonum multiflorum. Chin Tradit Herb Drugs,1993,24(3):115-118.
[39]宋士军,李芳芳,尹智玮,等.何首乌对实验性高脂血症作用的研究.河北中医 药学报,2003.18(4)：27-28.
[40]张伟,李锋,王玉琴,等.二苯乙烯苷对实验性动脉粥样硬化大鼠血脂和炎症因子的调节作用.中国临床药理学与治疗学,2007,12(5)：516-520.
[41]张伟,王春华,沈燕,等.二苯乙烯苷对实验性大鼠动脉粥样硬化的治疗作用.中国药科大学学报,2007,38(3)：261-264.
[42]高瑄,胡英杰,符林春.何首乌二苯乙烯苷的调节血脂作用.中国中药杂志,2007,32(4)：323-326.
[43]Shanhong Ling, Lina Nheu, Aozhi Dai, et al. Effects of four medicinal herbs on human vascular endothelial cells in culture. International Journal of Cardiology, 2008,128:350-358.
[44]王旻晨,吴开云,杨亚安.何首乌提取物对内皮细胞T-AOC、LPO、NO、SOD代谢的影响.中国现代医药杂志,2005,7(1)：34-36.
[45]方微,张慧信,王绿娅,等.何首乌总甙抗氧化与实验性小鼠主动脉粥样硬化病变的形成.中国中药杂志，2007,32(13)：1320-1323.
[46]Zhang W, Wang CH, Li F, et al.2,3,4',5-Tetrahydroxysti-1bene-2-O-beta-D-glucoside suppresses matrix metalloproteinase expression and inflammation in atherosclerotic rats. Clin Exp Pharmacol Physiol,2008,35(3):310-6.
[47]张伟,王春华,李锋.二苯乙烯苷对大鼠动脉硬化模型的MMP-2、9表达的影响.中国临床药理学杂志,2008,24(2)：134-138.
[48]Liu QL, Xiao JH, Ma R, et al. Effect of 2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside on lipoprotein oxidation and proliferation of coronary arterial smooth cells. Journal of Asian Natural Products Research,2007,9(8):689-697.
[49]汪德清,丁保国,Tomas G Neil,等.黄芪总黄酮对动脉粥样硬化早期形成的影响.中国药理学通报,2003,19(6)：637.
[50]杨五彪,陈群力,马灵筠,等.黄芪多糖对兔动脉粥样硬化血管内皮细胞功能的影响.陕西医学杂志,2005,34(8)：914-918.
[51]杨五彪,陈群力,马灵筠,等.黄芪多糖对兔动脉粥样硬化内皮素-1、C反应蛋白的影响.中华实用中西医杂志,2005,14(18)：317-319.
[52]张馨木,曲绍春,睢大员,等.人参Rb组皂苷对高脂血症大鼠血脂代谢的影响 及其抗氧化作用.中国中药杂志,2004,29(11)：1085-1088.
[53]赵艳威,于小风,徐华丽,等.人参果皂苷注射液对高脂血症大鼠血脂代谢的影响.吉林大学学报(医学),2005,31(3)：407-410.
[54]曲绍春,睢诚,于晓风,等.人参Rb组皂苷对大鼠实验性心肌缺血再灌注损伤的保护作用.吉林大学学报,2007,33(5)：849-852.
[55]防方,段胜仲.绞股蓝总皂甙对培养兔血.管平滑肌细胞基因表达的影响.湖北医科大学学报,1997,18(4)：297-299.
[56］许士凯,何红.绞股蓝总皂甙对氧化修饰低密度脂蛋白损伤小牛主动脉内皮细胞的防治作用,中国临床药理学与治疗学,2002,7(5)：389-340.
[57]李峰,刘小滨,卢银让,等.绞股蓝饮料降血脂功能.试验毒理学杂志,2006,20(4)：274.
[58]谭华炳,匡颖文.绞股蓝干预食饵兔动脉粥样硬化过程中对内皮素-1和C反应蛋白的影响研究.山西医药杂志,2006,35(10)：866-868.
[59]Hou YZ, Zhao GR, Yang J, et al. Protective effect of ligusticum chuanxiong and angelica sinensis on endothelial cell damage induced by hydrogen peroxide. Life Sci,2004,75(14):1775-1786.
[60]马渝,史若飞,文玉明等.虎杖抗动脉粥样硬化作用的实验研究.中国中医急症,2005,14(6)：564-566.
[61]肖铭甲,陈卫红,吴炜等.虎杖苷抑制ox-LDL诱导的脂质过氧化并下调巨噬细胞清道夫受体CD36表达.中国病理生理杂志,2010,26(7)：1280-1284.
[62]刘龙涛,吴敏,张文高等.虎杖苷对颈动脉粥样硬化斑块稳定性的干预研究.北京中医药,2009,28(3)：172-175.
[63]郑广娟,朱莹,王婷.虎杖配伍山楂抗动脉粥样硬化易损斑块病变的机制研究.中国病理生理杂志,2010,26(4)：635-639.
[64]熊一力,王宏伟.API0134对平滑肌细胞增殖和碱性纤维母细胞生长因子及相关癌基因表达的影响.中国动脉硬化杂志,1997,5(1)：45-47.
[65]王宏伟,赵华月,熊一力.穿心莲提出物对动脉粥样硬化家兔动脉壁PDGF-B、 c-sis和c-myc基因表达的影响.同济医科大学学报,1998,27(1)：46-48.
[66]康丽华,贺卫乎,曹军杰,等.穿心莲黄酮片治疗脑动脉粥样硬化的研究.镇江 医学院学报,2000,10(2)：237.
[67]赵咏梅,李发荣,杨建雄,等.连翘苷降血脂及抗氧化作用的实验研究.天然产物研究与开发：发,2005,17(2)：157-159.
[68]张立伟,刘金,杨频.中草药连翘提取物抗氧化活性研究.食品科学,2003,24(2)：122-125.
[69]贺圣文,赵仁宏,陈景武,等.马齿苋对家兔实验性动脉粥样硬化形成的作用.潍坊医学院学报,2003,25(3)：161.
[70]贺圣文,赵仁宏,吴洪娟,等.野生马齿苋对家兔动脉粥样硬化形成的影响.中华预防医学杂志,1997,31(2)：91.
[71]贺圣文,王春梅,赵仁宏,等.马齿苋抗动脉粥样硬化形成及延缓衰老的实验研究.预防医学文献信息,1996,2(4)：322-323.
[72]余建清.半枝莲总黄酮对红细胞膜脂质过氧化损伤的保护作用.中国药师,2005,8(11)：897.
[73]李瑞峰,温海涛.半边莲不同组分对内皮细胞内皮素及内皮源一氧化氮合酶代谢的影响.中国动脉硬化杂志,2002,10(1)：19.
[74]于永芳,高瑞峰,李沈明.黄芩茎叶总黄酮对动咏粥样硬化早期病理改变的影响.中草药,2003,34(11)：1033-1034.
[75]佟继铭,陈光晖,刘玉玲,等.黄芩茎叶总黄酮对家兔实验性动脉粥样硬化的预防作用.中草药,2005,36(1)：93-94.
[76]文川,徐浩,黄启福,等.活血中药对ApoE基因缺陷小鼠血脂及动脉粥样硬化斑块炎症反应的影响.中国中西医结合杂志,2005,25：345.
[77]李自成,常青,巫少荣.瓜蒌注射液对兔主动脉平滑肌细胞增殖的影响.新中医,2000,32(5)：33-34.
[78]王冬梅,代世元,芦丽莉,等.瓜蒌皮提取物对大鼠动脉粥样硬化保护作用的实验研究.北华大学学报,2008,9(2)：128-131.
[79]王姗姗.瓜萎皮的药理作用及其临床应用.山西医药杂志,2009,38(1)：67.
[80]宋宏雁,班努·库肯.瓜萎皮注射液治疗不稳定型心绞痛疗效观察.现代中西医结合杂志,2009,18(31)：3820-3821.
[81]蒋文跃,杨宇.化痰药半夏、瓜蒌、浙贝母、石菖蒲对大鼠血液流变性的影 响.中医杂志,2002,43(3)：215.
[82]沈雅琴,张明发.半夏的镇痛、抗溃疡和抗血栓形成作用.中国生化药物杂志,1998,19(3)：141.
[83]吉中强,宋鲁卿,牛其昌.十五种理气中药体外对人血小板聚集的影响.中草药,2001,32(5)：428-430.
[84]吉中强,宋鲁卿,高晓析,等.11种中药对大鼠血小板聚集、红细胞血流变性的影响.山东中医杂志,2000,19(2)：107-108.
[85]刘贵京,张华云.山楂对冠心病同型半胱氨酸血症的影响.中国病理生理杂志,2002,18(11)：1332-1333.
[86]刘春丽,张凤林,李明凯,等.山楂提取物对心肌缺血／再灌注损伤的保护作用.心脏杂志,2006,18(2)：127.
[87]王云来,樊守艳,韩进.山楂丹参合用调节血脂作用的实验研究.浙江中医药大学学报,2006,30(5)：468.
[88]郑勇英,杨隽,潘喜华,等.银含叶抗衰老和调节血脂的实验研究.上海预防医学杂志,2000,12(2)：71
[89]陈临溪,王蓉蓉,黄红林,等.银杏叶提取对饲养高胆固醇兔动脉粥样硬化和低密度脂蛋白体外氧化的作用.心肺血管病杂志,2001,20(1)：46.
[90]张荣怀,李源,王晓明,等.银杏黄酮甙对人巨细胞病毒感染促进动脉粥样硬化发生和发展的保护作用.中国临床康复,2004,8(6)：1714-1715.
[91]刘宇,顾仁樾,王逸平.银杏胶囊防治兔动脉粥样硬化的实验研究.中医杂志,2003,44(2)：133-134.
[92]吴兴利,王士雯,徐雅琴.银杏叶提取物对兔血管平滑肌细胞分泌细胞因子的影响.中国新药与临床杂志,2003,22(5)：292-293.
[93]吕燕宁,王伟,张涛,等.葛根素对血管平滑肌细胞凋亡及其相关基因表达的影响.中华临床医药,2002,3(1)：9.
[94]荆涛,王绿娅,王伟,等.葛根素调节血管平滑肌细胞凋亡相关基因在斑块组织中表达的研究.中国药学杂志,2003,38(9)：667-670.
[95]Hong Y, ShaoHuaH, Zi Ren S. Inhibition of Neuropeptide-Y-induced Vascular Smooth Muscle Cell Proliferation with Pueraria Lobata Isoflavone广州中医药大学 学报,2005,22(3)：203.
[96]甄艳军,安杰,周晓红，木贼对动脉粥样硬化早期大鼠血清IL-1、IL-8及TNF-α的影响.中国老年学杂志,2003,23(8)：1714-1715.
[97]甄艳年,安杰,侯建明.木贼对动脉粥样硬化早期大鼠内皮细胞凋亡及Bax、Bcl-2表达的影响.中国老年学杂志,2003,23(5)：305-304.
[98]刘丽梅,高政,李宝文,等.余甘子对实验性颈动脉粥样硬化家兔的影响.中国临床康复,2003,7(5)：766-767.
[99]王素敏,张杰,李兴琴.车前子对高脂血症大鼠机体自由基防御机能的影响.中国老年学杂志,2003,23(8)：529-530.
[100]秦建国,王亚红,梁晋普,等.泽泻萜帖类化合物对ApoE基因敲除动脉粥样硬化小鼠肝脏基底膜HSPG的调节作用.中华中医药学刊,2007,25(4)：696-697.
[101]工亚利,司秋菊,王鑫国,等.蜈蚣对动脉粥样硬化家兔血管平滑肌细胞周期及c-myc基因表达的影响.中药药理与临床,2001,17(6)：28.
[102]王雁萍,魏重琴.酸枣仁皂甙A对血管平滑肌细胞增值及SIS基因表达的影响.心肺血管病杂志,2002,21(1)：43-44.
[1]Valgimigli M, Agostoni P, Serruvs PW. Acute coronary syndromes:an emphasis shift from treatment to prevention, and the enduring challenge of vulnerable plaque detection in the cardiac catheterization laboratory. J Cardiovasc Med(Hagerstown), 2007,8(4):221-229.
[2]王涛,浦艳华,殷洁,等.易损斑块与急性冠咏综合征.心血管病学进展,2007,28(2)：246-248.
[3]Lerakis S, Synetos A, Toutouzas K, et al. Imaging of the vulnerable plaque: Noninvasive and Invasive techniques. Am J Med Sci,2008,336(4):342-348.
[4]Achenbach S, Moselewski F, Ropers D, et al. Detection of calcified and noncalcified coronary atherosclerotic plaque by contrast-enhanced, bmillimeter multidetector spiral computed tomography: a segment-based comparison with intravascular ultrasound. Circulation,2004,109(1):14-17.
[5]Leber AW, Knez A, Becker A, et al. Accuracy of multidetector spiral computed tomography in identifying and differentiating the composition of coronary atherosclerotic plaques:a comparative study with intracoronary ultrasound. J Am Coll Cardiol,2004,43(7):1241-1247.
[6]Caussin C, Ohanessian A, Ghostine S, et al. Characterization of vulnerable nonstenotic plaque with 16-slice computed tomography compared with intravascular ultrasound. Am J Cardiol,2004,94(1):99-104.
[7]Viles-Gonzalez JF, Poon M, Sanz J, et al. In vivo 16-slice, multidetector-row computed tomography for the assessment of experimental atherosclerosis: comparison with magnetic resonance imaging and histopathology. Circulation,2004, 110(11):1467-1472.
[8]Inoue F, Sato Y, Matsumoto N, et al. Evaluation of plaque texture by means of multislice computed tomography in patients with acute coronary syndrome and stable angina. Circulation,2004,110:1467-1472.
[9]Moselewski F, Ropers D, Pohle K, et al. Comparsion of measurement of cross-sectional coronary atherosclerotic plaque and fessel areas by 16-slice multidetector computed tomography versus intravascular ultrasond. Am J Cardiol, 2004,94:1294-1297.
[10]Leber AW, Knez A, von Ziegler F, et al. Quantification of obstructive and nonobstructive coronary lesions by 64-slice computed tomography:a comparative study with quantitative coronary angiography and intravascular ultrasound. J Am Coll Cardio,2005,46:147-154.
[11]Leschka S, Scheffel H, Desbiolles L, et al. Image quality and reconstruction intervals of dual-source CT coronary angiography:recommendations for ECG-pulsing windowing. In vest Radiol,2007,42:543-549.
[12]Schroeder S, Kuettner A, Leitritz M, et al. Reliability of differentiating human coronary plaque morphology using contrast-enhanced multislice spiral computed tomography:a comparison with histology. J Comput Assist Tomogr,2004,28: 449-454.
[13]Yuan C, Mitsumori LM, Beach KW, et al. Carotid atherosclerotic plaque: noninvasive MR characterization and identification of vulnerable lesions. Radiolgy, 2001,221:285-299.
[14]Wilensky RL, Song HK, Ferrari VA. Role of magnetic resonance and intravascular magnetic resonance in the detection of vulnerable plaques. J Am Coll Cardiol,2006,47(suppl 8):C48-C56.
[15]Hatsukami TS, Rose R, Polissar NL, et al. Visualization of fibrous cap thickness and rupture in human atherosclerotic carotid plaque in vivo with high-resolution magnetic resonance imaging. Circulation,2000,102:959-964.
[16]Trivedi RA, Mallawarachi C, U-King-Im JM, et al. Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler Thromb Vase Biol,2006,26:1601-1606.
[17]Ruehm SG, Corot C, Vogt P, et al. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation,2001,103:415-422.
[18]Sirol M, Itskovich VV, Mani V, et al. Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. Circulation,2001, 103:1601-1606
[19]Steen H, Warren WP, Desai M, et al. Combined transesophageal and surface MRI provides optimal imaging in aortic atherosclerosis. J Cardiovasc Magn Reson, 2004,6:909-916.
[20]Ohtsuki K, Hayase M, Akashi K, et al. Detection of monocyte chemoattractant protein-1 receptor expression in experimental atherosclerotic lesions:an autoradiographic study. Circulation,2001,104(2):203-208.
[21]Iuliano L, Signore A, Vallabajosula S, et al. Preparation and bio-distribution of 99m technetium labeled oxidized LDL in man. Atherosclerosis,1996,126(1): 131-141.
[22]Kopka K, Breyholz HJ, Wagner S, et al. Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo. Nucl Med Biol,2004,31(2):257-267.
[23]Kolodgie FD, Edwards S, Petrov A, et al, Noninvasive detection of matrix metalloproteinase upregulation in experimental atherosclerotic lesions and its abrogation by dietary modification (abstr). Circulation,2001,104(6):694.
[24]Kolodgie FD, Petrov A, Virmani R, et al. Targeting of apoptotic macrophages and experimental atheroma with radiolabeled annexin V: a technique with potential for noninvasive imaging of vulnerable plaque. Circulation,2003,108(25): 3134-3139.
[25]Zhao QM, Xu JP, Wang Q, et al. Noninvasive imaging of vulnerable plaque with radio labeled annexin V: expetimental study. Chin J Med Imaging Technol, 2005,21(9):1349-1352.
[26]Vallabojosula S, Machac K, Knesaurek J. Imaging atherosclerotic macrophage density by positron emission tomography using F-18 fluorodeoxyglucose (FDG). J Nucl Med,1996,37(Suppl 1):38.
[27]Rudd JII, Warburton EA, Fryer TD, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation,2002,105(23):2708-2711.
[28]Kotani J, Mintz GS, Castagna MT, et al. Intravascular ultrasound analysis of infarct-related and non-infarct-related arteries in patients who presented with an acute myocardial infarction. Circulation 2003; 107:2889-2893.
[29]von Birgelen C, Klinkhart W, Mintz GS, et al. Plaque distribution and vascular remodeling of ruptured and nonruptured coronary plaques in the same vessel:an intravascular ultrasound study in vivo. J Am Coll Cardiol,2001,37:1864-1870.
[30]Ehara S, Kobayashi Y, Yoshiyama M, et al. Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction:an intravascular ultrasound study. Circulation,2004,10(22):3424-3429.
[31]Maddux JT, Wink O, Messenger JC, et al. Randomized study of the safety and clinical utility of rotational angiography versus standard angiography in the diagnosis of coronary artery disease. Catheter Cardiovasc Interv,2004,62:164-174.
[32]Chen SJ, Carroll JD.3-D reconstruction of coronary arterial tree to optimize angiographic visualization. IEEE Trans Med Imaging,2000,19(4):318-336.
[33]Beckman JA, Ganz J, Creager MA, et a.l Relationship of clinical presentation and calcification of culprit coronary artery stenoses. Arterioscler Thromb Vasc Bio,1 2001,21 (10):1618-1622.
[34]Virmani R,Burke AP, Kolodgie FD, et al. Pathology of the thin-cap fibroatheroma:A type of vulnerable plaque. J Interv Cardiol,2003,16(3):267-272.
[35]De Korte CL. Intravascular ultrasound elastography: An overview. Ultrasonics, 2002,40:859-865.
[36]Schaar JA, De Korte CL, Mastik F, et al. Characterizing vulnerable plaque features with intravascular elastography. Circulation,2003,108:2636-2641.
[37]Komiyama N, Berry GJ, Kolz ML, et al. Tissue characterization of atherosclerotic plaques by intravascular ultrasound radiofrequency signal analysis: an in vitro study of human coronary arteries. Am Heart J,2000,140(4):565-574.
[38]Carlier S, Kakadiaris IA, Dib N, et al. Vasa vasorum imaging:A new window to the clinical detection of vulnerable atherosclerotic plaques. Curr Athero Rep,2005,7 (2):164-169.
[39]Stamper D, Weissman NJ, Brezinski M. Plaque characterization with optical coherence tomography. J Am Coll Cardiol 2006; 47(Supp18):C69-C79.
[40]Fujimoto JG, Boppart SA, Tearney GJ, et al. High resolution in vivo intra-arterial imaging with optical coherence tomography. Heart,1999,82:128-133.
[41]Brezinski M. Characterizing arterial plaque with optical coherence tomography. Curr Opin Cardiol,2002,17:648-655.
[42]Patel NA, Stamper DL, Brezinski ME. Review of the ability of optical coherence tomography to characterize plaque, including a comparison with intravascular ultrasound. Cardiovasc Intervent Radiol,2005.28:1-9.
[43]Bouma BE, Tearney GJ, Yabushita H, et al. Evaluation of intracoronary stenting by intravascular optical coherence tomography. Heart,2003,89(3): 317-320.
[44]Tearney GJ, Brezinski ME, Bouma BE, et al. In vivo endoscopic optical biopsy with optical coherence tomography. Science,1997,276(5321):2037-2039.
[45]Tearney GJ, Brezinski ME, Boppart SA, et al. Images in cardiovascular medicine. Catheter-based optical imaging of a human coronary artery. Circulation, 1996,94(11):3013.
[46]Mizuno K, Miyamoto A, Satomura K, et al. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. Lancet,1991,337:586-589.
[47]Miyamoto A, Prieto AR, Friedl SE, et al. Atheromatous plaque cap thickness can be determined by quantitative color analysis during angioscopy:implications for identifying the vulnerable plaque. Clin Cardiol,2004,27(1):9-15.
[48]Takano M, Mizuno K, Yokoyama S, et al. Changes in coronary plaque color and morphology by lipid-lowering therapy with atorvastatin:serial evaluation by coronary angioscopy. J Am Coll Cardiol,2003,42(4):680-686.
[49]Casscella W, Hathorn B, David M, et al. Thermal detection of celluar infiltrates in living atherosclerotic plaques:possible implica-tions for plaque rupture and thrombosis [J].Lancet,1996,347:1447-1449.
[50]Stefanadis C, Diamantopoulos L. Vlacho-poulos C, et al. Thermal heterogeneity within human atherosclerotic coronary arteries detected in vivo. A new method of detection by application of a special thermography catheter. Circulation,1999,99: 1965-1971.
[51]Fayad ZA, Fuster V. Clinical imaging of the high-risk or vulnerable atherosclerotic plaque. Circ Res,2001,89:305-316.
[52]Toutouzas K, Synetos A, Stefanadi E, et al. Correlation between morphologic characteristics and local temperature differences in culprit lesions of patients with symptomatic coronary artery disease. J Am Coll Cardiol,2007,49(23):2264-2271.
[53]Naghavi M, John R, Naguib S, et al. PH Heterogeneity of human and rabbit atherosclerotic plaques; a new insight into detection of vulnerable plaque. Atherosclerosis,2002,164:27-35.
[54]Khan, De Meyer GR, Van langenhove G, et al. In vivo temperature heterogeneity of atherosclerotic plaques in determined by plaque composition. Circulation,2002,105:1596-1601.
[55]Brennan JF Ⅲ, Romer TJ, Lees RS, et al. Histopathology of human coronary atherosclerosis by quantifying its chemical composition with Raman spectroscopy. Circulation,1998,97(9):878-885.
[56]Moreno PR, Lodder RA, Purushothaman KR, et al. Detection of lipid pool, thin fibrous cap, and inflammatory cells in human aortic atherosclerotic plaques by near-infrared spectroscopy. Circulation,2002,105(8):923-927.
[57]Hamdan A, Assali A, Fuchs S, et al. Imaging of vulnerable coronary artery plaques. Catheter Cardiovasc Interv,2007,70(1):65-74.
[58]Quick HH, Ladd ME, Hilfiker PR, et al. Autoperfused balloon catheter for intravascular MR imaging. J Magn Reson Imaging,1999,9(3):428-434.
[59]Worthley SG, Helft G, Fuster V, et al. A novel nonobstructive intravascular MRI coil:in vivo imaging of experimental atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology,2003,23(2):346-350.
[1]Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation,1979,59:607-609.
[2]中国中西医结合学会心血管专业委员会.冠心病中医辨证标准.中西医结合杂志,1991,11(5)：257.
[3]田德禄主编.中医内科学(第7版).北京：人民卫生出版社,2006.
[4]郭志华.冠心病心绞痛2432例中医辨证分型综合统计分析.湖南中医杂志,1998,14(2)：7-8.
[5]张琳,于鑫婷,徐浩.冠心病中医证候特点的分析与思考.中西医结合心脑血管病杂志,2009,7(5)：578-581.
[6]高铸烨,张京春,徐浩,等.用复杂网络挖掘分析冠心病证候-治法-中药关系.中西医结合学报,2010,8(3)：238-243.
[7]付长庚,高铸烨,陈静,等.京津地区冠心病证候-治法-方药的现况调查.中国实验方剂学杂志,2010,16(12)：176-179.
[8]]王雪华,夏春明,颜建军,等.中医证候分类中常用多元统计分析方法及应用评析.世界科学技术-中医药现代化思路与方法,2008,10(2)：15-20.
[9]王阶,何庆勇,李海霞,等.815例不稳定型心绞痛中医证候的因子分析.中西医结合学报,2008,8(6)：788-792.
[10]张晓东.温阳养阴法治疗不稳定性心绞痛的理论探讨及实验研究.南京中医药大学优秀硕士毕业论文集,2005.
[11]王瑞科,杨继平,李红.葛丹稳心汤对不稳定性心绞痛患者LPA影响的临床研究.湖南中医杂志,2007,23(2)：5-7.
[12]刘耀乾,李小苹.丹参滴丸和川芎嗪配合西药联合治疗不稳定型心绞痛临床观察.中国中西医结合杂志,2003,23(7)：544-545.
[13]徐浩,史大卓,殷惠军,等.“瘀毒致变”与急性心血管事件：假说的提出与临床意义.中国中西医结合杂志,2008,28(10)：934-938.
[1]Naghavi M, Libby P, Falk E, et al. From vulnerable Plaque to vulnerable Patient: a call for new definition and risk assessment strategies:Part Ⅰ. Circulation.2003, 108(14):1664-1672.
[2]Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med,1999; 340(2): 115-126.
[3]Hansson GK. Immune mechanism in atherosclerosis. Arteroscler Thromb Vasc Biol,2001; 21:1876-1890.
[4]徐浩,史大卓,殷惠军,等.“瘀毒致变”与急性心血管事件：假说的提出与临床意义.中国中西医结合杂志,2008,28(10)：934-938.
[5]文川,徐浩,黄启福,等.几种活血中药对ApoE缺陷小鼠动脉粥样硬化斑块影 响的形态学研究.中国病理生理杂志,2005,21(8)：864-867.
[6]周明学,徐浩,陈可冀,等.活血解毒中药有效部位对ApoE基因敲除小鼠动脉粥样斑块稳定性的影响.中国病理生生理杂志,2008,17(6)：588-591.
[7]Johnson J, Carson K, Williams H, et al. Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse:model characterization and effeets of pravastatin treatment. Circulation,2005,111(23):1422-1430.
[8]许淑云,卞如濂,陈修.药理实验方法学.第3版.北京：人民卫生出版社,2002：202-204.
[9]Suzuki H, Kurihara Y, Takeya M, et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature,1997,386(6622): 292-296.
[10]李莉,翟同均,陈融,等Movat五色套染法的改进及应用.临床与实验病理学志,2002,18(6)：660-662.
[11]Masashi S, Takashi I, Yasuhiko H, et al. Fibromuseular cap composition is important for the stability of established atheroselerotic plaques immature WHHL rabbits treated with statins. Atherosclerosis,2001,157(1):75-84.
[12]Johnson JL, Fritsche DR, Behrendt M, et al. Effect of broadspectrum matrix metalloproteinase inhibition on athero sclerotic plaque stability. Cardiovasc Res, 2006,71(4):586-595.
[13]张京春,陈可冀.瘀毒病机与动脉粥样硬化易损斑块相关的理论思考.中国中西医结合杂志,2008,28(4)：366-368.
[14]周明学,徐浩,陈可冀.中医脂毒、瘀毒与易损斑块关系的理论探讨.中国中医基础医学杂志,2007,13(10)：737-738.
[15]于俊生,陈兆昌.动脉粥样硬化从痰瘀毒论治探讨.山东中医杂志,2002,21(8)：451-453.
[16]卢笑辉.论热毒在急性冠脉综合征发病中的作用.中国中医急症,2005,14(8)：750-751.
[17]徐浩,文川,陈可冀,等.川芎、赤芍及其有效部位配伍对载脂蛋白E基因缺陷小鼠动脉粥样硬化斑块稳定性影响的研究.中国中西医结合杂志,2007,27(6)：513-518.
[18]张京春,陈可冀,刘剑刚,等.解毒活血配伍方药对载脂蛋白E基因敲除小鼠血清超敏C反应蛋白的影响.中国中西医结合杂志,2008,28(4)：330-333.
[19]张京春,陈可冀,郑广娟,等.解毒活血中药配伍对载脂蛋白E基因敲除小鼠主动脉NF-κB和MMP-9表达的调控作用.中国中西医结合杂志,2007,27(1)：40-44.
[20]刘剑刚,董国菊,史大卓,等.气血并治方提取物对ApoE基因缺陷小鼠动脉粥样硬化病理形态和基质金属蛋白酶-1及其抑制物表达的影响.中国药学杂志,2008,43(22)：1700-1705.
[21]刘运芳,赵玉霞,于会明,等.祛瘀消斑胶囊对实验性动脉粥样硬化斑块组织学构成的影响.上海中医药大学学报,2005,19(3)：34-35.
[22]常章富.中药学.北京：中国医药出版社,2001：108.
[23]张京春.解毒活血干预动脉粥样硬化易损斑块的综合研究.山东中医药大学博士毕业论文,2007.
[24]孙小玲.三七的研究进展.云南中医中药杂志,2005,26(6)：44-46.
[25]腾勇荣,张永清.瓜蒌化学成分研究进展.山东中医药大学学报,2011,35(1)：85-86.
[26]腾勇荣,王连侠.张水清.瓜蒌药理研究进展.齐鲁药事,2010,29(7)：417-418.
[27]彭晓波.何首乌的研究和应用.中国现代药物应用,2008,2(19)：117.
[28]周明学,徐浩.陈可冀,等.活血解毒中药有效部位对ApoE基因敲除小鼠血脂和动脉粥样硬化斑块炎症反应的影响.中国中西医结合杂志,2008,28(2)：126-130.
[29]文川,徐浩,黄启福,等.活血中药对ApoE基因缺陷小鼠血脂及动脉粥样硬化斑块炎症反映的影响.中国中西医结合杂志,2005,25(4)：345-349.
[30]周明学,徐浩,潘琳,等.活血、益气、化痰中药对ApoE基因敲除小鼠主动脉粥样硬化斑块炎症反应的影响.中国中医急症,2008,17(4)：496-498.
[31]曾昭均主编.均匀设计及其应用.沈阳：辽宁人民出版社,1994：5.
[32]Zaman AG, Helft G, Worthley SG, et al. The role of Plaque rupture and thrombosis in coronary artery disease. Atheroselerosis,2000,149:251-266.
[33]Giroud D, Li JM, Urban P, et al. Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiograPhy. Am J Cardiol,1992,69:729-732.
[34]Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol,1988,12:56-62.
[35]Jiang C, Ting AT, Seed B. PPAR yagonists inhibit production of monocyte inflammatory cytokines. Nature,1998,391(6662):82-86.